Collaboration Agreement



 Exhibit 10.8 

COLLABORATION AGREEMENT 
 This COLLABORATION AGREEMENT is entered into as of November 9, 2005 (the “Effective Date”), by and between PAIN THERAPEUTICS, INC., a Delaware corporation having an address of 416
Browning Way, South San Francisco, California 94080 (“PTI”), and KING PHARMACEUTICALS, INC., a Tennessee corporation having an address of 501 Fifth Avenue, Bristol, Tennessee 37620 (“King”). Each of King and PTI is
sometimes referred to individually herein as a “Party” and collectively as the “Parties.” 

WHEREAS, PTI owns or controls certain technology and intellectual property rights relating to the preparation of tamper-resistant opioid
formulations; 
 WHEREAS, King is engaged in the development and marketing of human therapeutics; 

WHEREAS, King is entering into this Agreement based on, among other things, PTI’s specialized skill, knowledge, and expertise with
respect to the technology and intellectual property relating to the preparation of tamper-resistant opioid formulations; and 

WHEREAS, the Parties desire to enter into a collaboration for the purpose of Developing Remoxy and other Products and to give King the
right to Market and manufacture Products, in each case, derived from PTI technology and intellectual property; 
 NOW,
THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration the receipt and sufficiency of which are acknowledged by the Parties, the Parties hereto, intending to be legally bound, agree as
follows. 
  

	1.	DEFINITIONS 


Capitalized words and phrases used in this Agreement have the meanings ascribed to such terms in Annex A attached hereto.

  

	2.	ADMINISTRATION OF THE COLLABORATION 

 2.1 Establishment and Function of JOC. PTI and King shall establish the JOC within thirty (30) days of the Closing Date, which shall have the responsibilities set forth in this
Agreement, including Section 2.2. Each Party shall appoint, in its sole discretion, three members to the JOC (which members shall be employees of such Party), with those members designated primarily to represent such Party with respect to
clinical/regulatory, sales/marketing/finance and manufacturing matters. King and PTI each shall designate a co-chairman (each a “Co-Chairman” and together the “Co-Chairmen”). Upon the approval of both Co-Chairmen
(or the remaining Co-Chairman in the event of a substitution in that position), which approval shall not be unreasonably withheld, each Party may substitute individuals, on a permanent or temporary basis, for any of its previously designated
representatives to the JOC, by giving written notice thereof to the other Party. PTI and King shall each bear all out-of-pocket expenses of their respective JOC members related to their participation on the JOC and attendance at JOC meetings.

 2.2 JOC Responsibilities. The JOC shall administer and monitor all matters with respect to the Collaboration,
including the following matters: 
 2.2.1 oversight of the Development Plans and Manufacturing/CMC Plans, including all related
strategy and objectives, timelines and activities thereunder, and changes with respect thereto on a quarterly basis; such oversight will confer to each Party, through its JOC representative, an ongoing right of Consultation; 

  
 1 








 2.2.2 review and approval of all budgets to support the Program Plans; 

2.2.3 review of the management and allocation of resources of the Collaboration; 

2.2.4 review of all Patent Rights and Technology used in connection with Product; 

2.2.5 review and approval (prior to execution by either Party) of (a) all Third Party licenses (including all amendments thereto),
and (b) all subcontracts, sublicenses, and other agreements (including all amendments thereto) that are required or to be entered into in connection with the Development Program and that either (i) require payments by a Party to a Third
Party of greater than one hundred thousand U.S. dollars ($100,000) over the life of the contract or (ii) are otherwise material, or reasonably likely to become material, to the Collaboration, such review in each case to include a determination,
with respect to each such subcontract, sublicense, license, or agreement, regarding whether it is appropriate to require the inclusion of the protections set forth in Section 3.8 hereof; and 

2.2.6 performance of such other functions as appropriate to further the purposes of this Agreement and the Collaboration as determined
from time to time by the Parties. 
 2.3 Dispute Resolution. 

2.3.1 In the event that the JOC shall not be able, within 10 days, to reach a decision or take an action on any matter, then such
unresolved matter shall first be referred for resolution to the Chief Executive Officer of each Party for attempted resolution by good faith negotiation. Such good faith negotiation may include the appointment by either Party, at its own expense, of
an unaffiliated Consultant, who shall be an expert chosen based on such person’s experience and expertise in the particular type of issue that is unresolved to advise such officers on the matter. 

2.3.2 If such officers are unable to resolve the matter within 10 days, then, except as provided in Section 3.4.6 or 3.9, and
subject to Section 3.3.2: 
 (a) the following matters shall be finally decided by PTI: (i) all matters related to
the Development Plan in the U.S. Territory until immediately prior to the Phase II Meeting with respect to a Product (subject to Section 3.4.3); and (ii) all CMC matters relating to the Manufacturing/CMC Plan through the Regulatory
Approval of an NDA for a Product; 
 (b) the following matters shall be finally decided by King: (i) all matters related
to the Development Plan in the U.S. Territory after the Regulatory Approval of an NDA for a Product; (ii) all matters relating to the Development Plan in the ROW; (iii) all CMC matters relating to the Manufacturing/CMC Plan after the
Regulatory Approval of an NDA for a Product; (iv) all non-CMC matters relating to the Manufacturing/CMC Plan that impact commercial supply (i.e., matters relating to choice of secondary packaging, secondary labeling, logistics, and the
like); and (v) all matters relating to the Yearly Brand Plan; and 
 (c) notwithstanding the foregoing provisions of this
Section 2.3.2, neither Party shall have final decision-making authority with respect to the following: (i) all matters related to the Development Plan in the U.S. Territory during the period immediately prior to the Phase II Meeting until
the Regulatory Approval of an NDA for a Product (subject to Section 3.4.3) and (ii) all other matters not otherwise described in Sections 2.3.2(a) and (b) above, including, subject to the parameters set forth in Sections 3.3.2 and
3.7, final decisions with respect to budgets and spending funds in excess of approved budgets (or in excess of one hundred ten percent (110%) of the funds allocated under the budget of a Development Plan, as provided in Section 3.7.2).

 2.3.3 Disputes not subject to the final decision-making authority of either Party, as described in Section 2.3.2(c)
above, will be resolved by binding arbitration in accordance with the rules of the American Arbitration Association (the “AAA”), unless another non-profit professional dispute resolution organization knowledgeable with respect to
drug development is agreed to by the Parties within five (5) days, and the provisions of this Section 2.3.3. 

  
 2 








 (a) The Party desiring to initiate an arbitration proceeding will send a written notice to
the other Party requesting the commencement of the arbitration proceeding and specifying the issue to be resolved. Following such notice, the JOC will work in good faith to select one neutral arbitrator, who will be an expert with respect to drug
development and the pharmaceuticals industry so as to better understand the legal, business, and scientific issues addressed in the arbitral proceeding. In the event that, within 10 business days of such notice, the JOC is unable to agree upon an
arbitrator, who is available to participate in the arbitration proceeding, then, each Party will designate one neutral arbitrator within 15 days thereafter. Within an additional 15 days thereafter, the first two arbitrators will designate a third.
Each arbitrator will be a neutral arbitrator, who is an expert in drug development and the pharmaceuticals industry. If either Party fails to choose an arbitrator within the foregoing time period, the AAA (or equivalent organization) will choose an
arbitrator on behalf of that Party. Disputes about arbitration procedure will be resolved by the arbitrators or, failing agreement, by the AAA (or equivalent organization) in San Francisco, California. Unless otherwise agreed by the Parties, the
arbitration proceedings will be conducted in San Francisco, California. 
 (b) Within 5 days of the selection of the final
arbitrator, the Parties will deliver to the arbitrators a joint letter (i) stating each of the issues that is the subject of the dispute, (ii) setting forth each Party’s final position with respect to each such issue, and
(iii) directing the arbitrators to resolve the dispute by selecting the final position of one of the Parties; provided that, if the Parties cannot agree on a joint letter, each Party will submit a letter setting forth its position on each
issue, and the failure of any Party to submit such a joint letter will not prevent the arbitration from proceeding. In addition, each Party may submit with the joint letter supporting documentation for such Party’s final position or a request
that the arbitrators permit the Parties to undertake limited discovery. In resolving the dispute, the arbitrators will have no authority to make a decision on any issue other than by selecting the final position of one of the Parties. 

(c) An arbitration decision will be rendered in writing within 30 days of the submission of the letter described above, which award will
be final and binding on the Parties and will be deemed enforceable in any court having concurrent jurisdiction of the subject matter hereof and the Parties. In selecting the final position of one of the Parties, the arbitrators will have the
authority to grant specific performance and allocate costs between the Parties (excluding attorneys’ fees, which each Party must bear itself); provided that the arbitrators will have no authority to award punitive damages or any damages in
excess of the limitations contained in this Agreement. 
 2.4 Committees. The JOC shall have the right and power
to appoint and delegate its responsibilities to committees, and the composition and eligibility requirements for the same shall be agreed upon by the members of the JOC. Except as otherwise mandated by the JOC, each committee established by the JOC
shall be governed by the rules and guidelines applicable to the JOC set forth in this Agreement. 
 2.5 Meetings.

 2.5.1 Schedule of Meetings. The JOC shall establish a schedule of times for meetings, taking into account the
planning needs of the Development Program and the need of the JOC to consult and render decisions. In no event shall the JOC meet less frequently than quarterly. Meetings shall alternate between the respective offices of the Parties in
(i) Princeton, New Jersey or Cary, North Carolina and (ii) San Francisco, California, or another mutually agreed upon location; provided, however, that the Parties may mutually agree to meet by teleconference or video conference or may act
by a written memorandum executed by the members of the JOC. 
 2.5.2 Quorum; Voting; Decisions. At each JOC
meeting, the attendance of at least one member representing each Party shall constitute a quorum. All decisions of the JOC shall be made by unanimous vote. Representatives of each Party or of its Affiliates who are not members of the JOC may attend
JOC meetings or committee meetings as non-voting observers at the invitation of either Party with the prior approval of the other Party, which approval shall not be unreasonably withheld. 

2.5.3 Agenda and Minutes. An agenda for each JOC meeting shall be circulated no less than three days prior to the meeting,
to the extent practicable. The JOC shall keep accurate minutes of its deliberations 

  
 3 








 
that record all proposed decisions and all actions recommended or taken. Drafts of the minutes shall be delivered to the members of the JOC within a reasonable time, not to exceed 10 days after
the meeting. The responsibility for the preparation and circulation of the draft minutes shall alternate between the Parties. Draft minutes then shall be edited by the Co-Chairmen and shall be issued in final form within a reasonable time not to
exceed 14 days after the meeting. 
  

	3.	DEVELOPMENT PROGRAM 


3.1 Development of Products. 
 3.1.1 Initial Product Designations. The Parties shall Develop no less than four (4) Products under the Collaboration. The Parties agree that the first such Product shall be Remoxy, the
second such Product shall be a product within the Field containing hydromorphone as its opioid API, and the third such Product shall be a product within the Field containing hydrocodone as its opioid API. The fourth Product, and all additional
Products, shall be selected as set forth in Section 3.1.2 below. 
 3.1.2 Designation of Additional Products.
In Consultation with PTI and review by the JOC and in accordance with the strategies of the Program Plans, King shall have the right to designate which products within the Field, in addition to the three (3) Products listed in
Section 3.1.1 above, shall be selected for Development and Marketing under the Development Program. Upon King’s designation of a product within the Field for inclusion in the Development Program, PTI shall inform Durect of such selection,
and provided that such product is a product that may be developed under the DLA, PTI shall exercise its rights under Section 2.1 of the DLA to designate such product a “Licensed Product,” and the Parties shall thereafter promptly
generate the Program Plans for such Product, all as further described in this Article 3. 
 3.1.3 Minimum Development and
Marketing Obligations. 
 (a) King shall ensure that it is Marketing or funding the Development of a minimum of at
least three (3) different Products under the Collaboration at all times; provided that beginning on October 1, 2006, such minimum number of different Products shall increase to four (4). In order to satisfy the foregoing requirement that
King is Marketing or funding the Development of at least four (4) different Products under the Collaboration by October 1, 2006, King further agrees that it will designate a fourth Product to be Developed and Marketed hereunder no later
than May 31, 2006. King further agrees that in the event King (i) does not designate a fourth Product by May 31, 2006 or (ii) notifies PTI of its intention to terminate Development and Marketing of a Product pursuant to
Section 3.1.4, is required pursuant to Section 3.1.4 to designate a replacement Product, and fails to select such a replacement Product within the applicable time frame specified thereunder (and such failure would result in a default of
King’s obligations under this Section 3.1.3), PTI will be entitled to designate such Product on King’s behalf. For purposes of this Section 3.1.3, King shall be deemed to be “funding the Development” of a Product if
King has (A) designated such Product for inclusion within the Collaboration pursuant to Section 3.1.2, (B) has used commercially reasonable efforts to have the JOC promptly approve a Development Plan and Manufacturing/CMC Plan for
such Product, and (C) is meeting its material funding obligations under all existing Program Plans. 
 (b) Subject to
King’s satisfaction of its funding obligations pursuant to Section 3.1.3(a) above, PTI shall ensure that it is Developing, together with the Products King is Marketing, a minimum of at least three (3) different Products under the
Collaboration at all times; provided that beginning on October 1, 2006, such minimum number of different Products shall increase to four (4). 
 3.1.4 Product Termination. King shall have the right to terminate Development and Marketing of a Product (the “Terminated Product”) hereunder by providing written notice to
PTI ninety (90) days prior to the effective date of such termination and, if necessary to comply with its obligations for maintaining a minimum number of Products, as provided in Section 3.1.3(a) above, designating a replacement Product in
such notice, which shall be treated as a Product designation in accordance with Section 3.1.2 above, and the provisions of Section 9.2.2(a) shall apply to such Terminated Product in all respects. If a replacement Product is required to be
designated, such notice of termination for such Terminated Product shall not be effective until a replacement Product has been selected and a Development Plan for such replacement Product has been approved by the JOC. 

  
 4 








 3.2 Durect License Agreement. Notwithstanding anything herein to the contrary,
King acknowledges and agrees that PTI is subject to certain obligations under the Durect License Agreement as set forth in Section 2.4 of the License Agreement. 
 3.3 Program Plans. Disputes relating to the matters set forth in this Section 3.3 will be governed by Section 2.3.2. 

3.3.1 Generally. In consultation with the JOC and in accordance with the strategy and objectives of the Program Plans, each
Party shall be primarily responsible for those tasks assigned it as set forth in each Program Plan and such obligations set forth in this Agreement. The Parties will take such actions necessary to define, generate, and approve the Program Plans for
each Product following the Effective Date. The Parties shall ensure that the Program Plans, including all timelines set forth therein, are consistent with each other, accurately reflect the objectives of the Development Program, and meet all of
PTI’s obligations to Durect under the DLA. Each Program Plan shall be in writing and shall set forth objectives and tasks to be performed by each of the Parties for the period covered by the Program Plan as agreed by such Party and as
specifically set forth in this Agreement. Any Program Plan may be amended at any time in accordance with the same procedures applicable to the adoption thereof. Although not specifically a part of a Program Plan, all issues and activities relating
to Patent Rights and Technology used in connection with a Product shall be subject to review of the JOC. 
 3.3.2 Program
Plan Budgets. 
 (a) Each Program Plan shall set forth an annual budget with respect to all material tasks required to
be conducted by the Parties pursuant to such Program Plan. Each Party shall use commercially reasonable efforts to complete all tasks assigned to it pursuant to the Program Plans in accordance with the funding allocated to such tasks in the budget.
All overruns and additional expenditures will be governed by Section 3.7. 
 (b) PTI will provide the JOC with updated
budgets for each Development Plan and Manufacturing/CMC Plan on a semiannual basis, which updated budgets shall specify the funding which PTI projects to be required during the following six (6) months to perform its obligations under such
Development Plans and Manufacturing/CMC Plans. Each such budget will be subject to review and approval of the JOC (such approval not to be unreasonably withheld); provided that it is understood that such budgets may include expenses for Third Party
services extending beyond the six (6)-month period covered by such budget if incurring such expenses is contractually required in obtaining such services. 
 (c) Notwithstanding anything to the contrary herein, the Parties agree that the Collaboration Costs budgeted for PTI’s activities under the Development Plan(s) and Manufacturing/CMC Plan(s) with
respect to Remoxy between the Closing Date and December 31, 2006 shall be at least seventeen million U.S. dollars ($17,000,000). The Parties further agree that King’s financial commitment with respect to Products other than Remoxy shall be
commensurate with the foregoing commitment to Remoxy, taking into account such factors as the stage of development and potential market of such Products relative to the stage of development and potential market of Remoxy and the regulatory strategy
with respect to the Product; provided that the total Collaboration Costs budgeted for PTI’s activities under the Development Plans and Manufacturing/CMC Plans for all Products shall not exceed twenty-five million U.S. dollars ($25,000,000) a
year in any of the first five (5) Calendar Years following the inception of this Agreement, or a cumulative total of one hundred million U.S. dollars ($100,000,000). Notwithstanding the foregoing, the Parties agree that the JOC may (but the
arbitrators may not) waive the preceding spending limits if, in its reasonable judgment, such increases in spending are warranted. For purposes of calculating the foregoing annual and cumulative spending limits, as well as the foregoing minimum
financial commitment with respect to Remoxy, Collaboration Costs as used in this section shall exclude (i) any milestone, royalty or sublicensing revenue payments to PTI, Durect, or others, (ii) costs of preparing Product for commercial
launch, including costs incurred in preparing to produce Product on a commercial scale, (iii) all costs and expenses related to filing, prosecution, enforcement, maintenance or defense of Patent Rights, and (iv) costs incurred in
connection with establishing or expanding manufacturing capacity for Product, it being understood that the actual amounts budgeted 

  
 5 








 
under the Program Plans in any given year must, in PTI’s reasonable opinion, be sufficient to permit PTI to remain in full compliance with the terms and obligations of the DLA and achieve
the prompt Development and Regulatory Approval of such Product in the U.S. Territory. The Parties further agree that with respect to Products subsequent to Remoxy, prompt Development and Regulatory Approval shall mean the speediest Development Plan
needed to reach Development and Regulatory Approval of any dosage form of such Products in the U.S. Territory, consistent with patients’ safety and all applicable regulatory rules and regulations. If the Program Plans need to be amended to
maintain these annual and cumulative limits, King will propose those amendments it believes are required, subject to review and approval of PTI, which approval shall not be unreasonably withheld. 

3.4 Development Plans. 
 3.4.1 PTI, in Consultation with King, will prepare, and provide the JOC with a copy of, a Development Plan for each Product, which will include pre-clinical, clinical, and regulatory timelines and an
annual budget, including a general overview of the expected schedule of meetings, discussions, and correspondence with Regulatory Authorities and the expected Regulatory Filings to be completed and maintained by the Collaboration. The Development
Plan will be subject to review and approval of the JOC, including ongoing review as provided in Section 2.2.1, which approval not to be unreasonably withheld; provided that the JOC shall not withhold its approval or otherwise object to the
budget in such Development Plan on any grounds that are inconsistent with the criteria and objectives set forth in Section 3.3.2(c) above. 
 3.4.2 Subject to Sections 3.4.5 and 3.4.6 below, the provisions of this Section 3.4.2 will apply to all matters relating to the Development Plan in the U.S. Territory. Until the Completion of Phase
II for a Product (but immediately prior to the Phase II Meeting), PTI, in Consultation with King, will have sole control and responsibility for execution of all matters described in the Development Plan with respect to a Product. Following the
Completion of Phase II for a Product but prior to the Regulatory Approval of an NDA for such Product, King and PTI will assume joint control and responsibility, through the JOC, for all matters described in the Development Plan with respect to such
Product; provided that PTI, in Consultation with King, will continue to be responsible for execution of matters under such plan. Following such Regulatory Approval, King, in Consultation with PTI, will have sole control and responsibility for
execution of all matters described in the Development Plan with respect to such Product. In addition, each Party will be given the opportunity to review and comment on draft and final development plans and all associated protocols, reports, and
Regulatory Filings on an ongoing basis. Draft documents will be provided to a Party in electronic or written form in advance of finalization or submission to Regulatory Authorities. 

3.4.3 In the event the FDA, during the Phase II Meeting for a Product, determines that the Development of such Product may not proceed to
Phase III, or the Parties otherwise agree that additional Development should be performed before proceeding to Phase III, King and PTI will jointly develop a revised Development Plan for such Product, and PTI will then reassume sole control and
responsibility for execution of such Development Plan until Completion of Phase II for a Product (immediately prior to the Phase II Meeting), as provided herein. 
 3.4.4 King, in Consultation with PTI, will have sole control and responsibility for execution of all Product Development and associated regulatory matters described in the Development Plan with respect to
a Product in the ROW. King, or its Affiliates or Sublicensees, shall be responsible for all clinical and regulatory expenses incurred in seeking Regulatory Approval in markets in the ROW. 

3.4.5 Upon the FDA’s approval of an NDA for a Product in the U.S. Territory, PTI, in Consultation with King, shall continue to have
sole control and responsibility for the execution of any post-approval commitments mandated by the FDA with respect to such Product and the first Regulatory Approval thereof, and King, in Consultation with PTI, shall assume sole control and
responsibility for execution of further Product Development of the Product. 
 3.4.6 In the event an NDA for Remoxy has not been
accepted for filing by the FDA within thirty (30) months of the Effective Date, King may elect to assume sole control and responsibility for execution of all matters under the Development Plan (and all CMC matters under the Manufacturing/CMC
Plans) with respect to Remoxy in the U.S. Territory by providing PTI with written notice thereof. In such event, notwithstanding the 

  
 6 








 
provisions of Section 2.3.2, PTI will not have final decision-making authority with respect to matters related to Remoxy under the Development Plan, but King will have the final
decision-making authority with respect to all such matters. Both Parties agree that such transfer of control and responsibility from PTI to King described in this Section 3.4.6 shall in no way diminish PTI’s or Durect’s right to
receive royalties or milestones, as provided in the License Agreement. King agrees to use commercially reasonable efforts to diligently proceed with execution of the Development Plan in good faith and consistent with PTI’s obligations under the
DLA and this Agreement and shall use commercially reasonable efforts and diligence in Developing and seeking Regulatory Approval of Remoxy in the U.S. Territory in accordance with its business, legal, medical, and scientific judgment and in
undertaking investigations and actions required to obtain appropriate Regulatory Approvals necessary to market Remoxy in the U.S. Territory and to meet its obligations hereunder. In addition, following such transfer of control and responsibility,
King will provide PTI with such plans, budgets, data, and other information as PTI had been obligated to provide to King prior to the assumption of control by King under this Section 3.4.6. 

3.4.7 Upon transfer of control and responsibility of a Product, the Parties will cooperate with each other in effecting a Tech Transfer
of such matters to King with respect to such Product. 
 3.4.8 PTI shall use commercially reasonable efforts to complete all
tasks assigned to it pursuant to the Development Plans in accordance with the budget; provided, however, that PTI may spend the funds allocated to such task plus an additional 10% of such funds, which additional expenditures shall be paid by King.
If the actual costs under a particular Development Plan will likely exceed 110% of the funds allocated to such task, the provisions of Section 3.7 shall govern. 
 3.4.9 During the period in which the Parties share joint control of matters under the Development Plan, both Parties agree that only PTI may initiate or respond to FDA communications (including e-mail)
regarding a Product; provided, however, that PTI shall keep King informed regarding all important communications, whether written or oral, between PTI and the FDA and shall provide King with an opportunity to review and comment on all important
written correspondence (including all e-mail correspondence) and participate in all planned meetings and telephone calls, between PTI and the FDA. 
 3.4.10 All INDs and NDAs for a Product in the U.S. Territory will be owned and maintained in the name of PTI; provided that, upon Regulatory Approval of a Product, ownership and maintenance of INDs and
NDAs for such Product will be transferred to King. In connection with such transfer to King, PTI will transfer all underlying clinical data and regulatory filings in an electronic format, to the extent available, agreed upon by the Parties. PTI
shall transfer the NDA for each approved Product to King within sixty (60) days of the receipt of Regulatory Approval of such Product. PTI further agrees to transfer the applicable INDs, clinical data, and other regulatory filings within one
hundred twenty (120) days of the Regulatory Approval of the Product to which they relate. All INDs and NDAs for a Product in the ROW will be owned and maintained by King. PTI hereby grants King access to, and right of reference to, any INDs and
NDAs for Products in the Territory owned and maintained in the name of PTI to the extent necessary for King to perform its obligations hereunder or conduct Product Development in the Territory. King hereby grants PTI access to, and right of
reference to, any INDs and NDAs for Products in the Territory owned and maintained in the name of King to the extent necessary for PTI (a) to perform its obligations hereunder, (b) to develop products that are within the Field (including
Products) outside the Territory, (c) to develop Crain/Shen SABER Drugs pursuant to the terms of this Agreement and the License Agreement, (d) to develop products outside the Field, including Crain/Shen Drugs, or (e) as otherwise
reasonably requested by PTI. For purposes of clarity, the rights granted by King to PTI in the preceding sentence shall include the right to permit Third Parties to access or reference such Regulatory Filings, so long as such Third Parties have
agreed to confidentiality obligations that are at least as stringent as those set forth herein; provided that PTI agrees that it will not provide such rights of access or reference to Third Parties who are not engaged in a research, development,
manufacturing, or marketing relationship with PTI. 
 3.4.11 PTI will use commercially reasonable efforts and diligence in
Developing and seeking Regulatory Approval of each Product in the U.S. Territory in accordance with its business, legal, medical, and scientific judgment and in undertaking investigations and actions required to obtain appropriate Regulatory
Approvals necessary to market Products in the U.S. Territory and to meet its obligations hereunder. 

  
 7 








 3.4.12 Subject to Section 2.1.4 of the License Agreement, following the acceptance for
review by a Regulatory Authority in the U.S. Territory of an NDA for a Product, King will use commercially reasonable efforts and diligence in conducting Product Development and seeking Regulatory Approval of such Product in the Major Market
Countries in the ROW in accordance with its business, legal, medical, and scientific judgment and in undertaking investigations and actions required to obtain appropriate Regulatory Approvals necessary to market such Product in the Major Market
Countries and to meet its obligations hereunder. In exercising its business, legal, medical, and scientific judgment, King may take the following factors, among other things, into consideration: (a) the existing and reasonable potential market
for a Product in a country, (b) any unduly burdensome regulatory requirements related to the Product Development of or the filing, acquisition, or maintenance of a Regulatory Approval for a Product in a country, (c) unduly burdensome
government restrictions or quotas on use of products containing opioids, (d) availability of and potential pricing or reimbursement for a Product in a country to allow a reasonable rate of return considering costs of Marketing such product in
such country, and (e) reasonable risk of Products sold in a country becoming gray-market goods in other markets and countries in the Territory; provided that the level of efforts and diligence used by King in conducting Product Development and
seeking Regulatory Approval of Products in the ROW shall at all times be at least a level of efforts sufficient to ensure that PTI’s obligations to Durect under the DLA are satisfied. Notwithstanding anything herein or in the License Agreement
to the contrary, in the event PTI obtains Regulatory Approval for a Crain/Shen SABER Drug in any country in the Territory, including a Major Market Country, before King obtains in such country Regulatory Approval for the Product that contains the
same opioid agonist as its API as such Crain/Shen SABER Drug, King shall not be obligated to conduct Product Development, seek Regulatory Approval, or Market such Product in such country. 

3.5 Manufacturing/CMC Plans. 
 3.5.1 King and PTI will jointly prepare each Manufacturing/CMC Plan and provide a copy to the JOC for its review and approval. Notwithstanding the foregoing, the Parties agree that PTI shall be solely
responsible for preparing a Manufacturing/CMC Plan for Remoxy, it being understood that King will be given an opportunity to review and offer recommendations regarding such plan during its preparation, which recommendations PTI will consider in good
faith. 
 3.5.2 PTI, in Consultation with King, will have control and responsibility for execution and implementation of all CMC
development of a Product throughout the Territory until the first Regulatory Approval for such Product in the applicable country, including responsibility for provision of CTM, CMC information for such Product in Regulatory Filings, and pre-market
validation of such Product. Notwithstanding the foregoing, PTI, in Consultation with King, will continue to have control and responsibility for execution and implementation of all CMC development after the first Regulatory Approval of a Product for
all changes in formulation, including changes in dosage strength, requiring a further pre-market clearance by the FDA or other Regulatory Authority. Such changes in formulation may include line extension developments or reformulations that are, in
PTI’s reasonable judgment, within the scope of the DLA. For purposes of clarity, with respect to novel Product formulations, PTI and Durect shall be responsible for determining the qualitative and quantitative composition of each novel
formulation with respect to excipients and API and setting technical and regulatory specifications for each such excipient and API used in creating such novel formulation. King shall have the right to select the manufacturer of such excipients and
API prior to the manufacture of Phase III CTM, so long as the excipients supplied by King’s selected manufacturer comply with the technical and regulatory specifications set by PTI and Durect. King shall have the right to negotiate and enter
into supply agreements for API and excipients and to be the assignee with respect to agreements that may be in place for such Product excipients and API as of the Effective Date, in each case to the extent permitted under such supply agreements, and
in compliance with the DLA and Section 2.1.3 of the License Agreement. 
 3.5.3 Except as provided in Section 3.5.2
above, King, in Consultation with PTI, will have control and responsibility for execution and implementation of post-approval support of each Product immediately upon the Regulatory Approval of an NDA for such Product, including logistics planning
relating to such Product. To the extent PTI is obligated to purchase any excipients, additives, solvents, API, bulk form of Product, or other ingredients or materials from Durect pursuant to the terms of the DLA and which ingredients or materials,
under the terms of the DLA, would be required to be used by King in its manufacture of Products, PTI shall sell to King such ingredients or materials so purchased by PTI at PTI’s actual cost, without any mark-up. In connection with the transfer
of control and responsibility, upon filing of an NDA for a Product, the Parties will cooperate with each other 

  
 8 








 
to develop a plan for the completion of the Tech Transfer of such matters; and, with respect to all information, files, and documentation available as of the date of such NDA filing, within sixty
(60) days from the acceptance by a Regulatory Authority of the NDA filing for a Product, the Parties will complete the Tech Transfer of such matters, including transferring files necessary for chemistry and manufacturing, to King with respect
to such Product. Thereafter, the Parties will continue to perform Tech Transfer in a timely manner with respect to all other information, files, and documentation relating to such matters, including permitting King to witness pre-market validation
and manufacture and quality operations. PTI agrees to assist, as requested by King, in post-approval support (including providing technical assistance, troubleshooting, and provision of post-marketing clinical supplies) to maximize the market
opportunity for the Products and to assure uninterrupted supply. 
 3.5.4 In Consultation with King, PTI may enter into such
agreements covering the clinical supply and manufacture of Products as are reasonably necessary to accomplish the objectives and purposes of the Development Program; and King agrees to abide by the terms of any such agreements which King has
approved or which has been unanimously approved by the JOC pursuant to its oversight and approval functions set forth in Section 2.2.5. King may enter into such agreements covering the commercial supply and manufacture of component materials
and API following the Completion of Phase II as are reasonably necessary to accomplish the objectives and purposes of the Development Program. King may at any time enter into an agreement covering manufacture of commercial Product. 

3.5.5 The Parties agree that PTI’s existing plan for manufacturing and quality operations with respect to Remoxy will continue to be
followed by the Collaboration, with a commercial supply agreement being entered into with Mallinckrodt-Hobart as the primary manufacturer. King acknowledges that PTI’s current understanding with Mallinckrodt-Hobart contemplates a term for such
supply agreement of at least five (5) Calendar Years, following the Calendar Year of commercial launch in the United States. PTI, in Consultation with King, may continue negotiating an agreement with Mallinckrodt-Hobart; provided that any such
agreement will include a provision that the agreement may be assigned by PTI to a business partner or Affiliate, in PTI’s sole discretion; and provided further that PTI will cooperate with King to achieve the most advantageous economic terms
for manufacture of Remoxy, including exercising commercially reasonable efforts to incorporate a provision in the Mallinckrodt-Hobart supply agreement to allow PTI under certain circumstances to solicit competitive bids for manufacture of Product
that may be used to obtain more favorable supply terms from Mallinckrodt-Hobart or, if Mallinckrodt-Hobart elects not to match such more favorable terms, then which would permit PTI to substantially reduce its obligation to purchase Product from
Mallinckrodt-Hobart following the third commercial year. The Mallinckrodt-Hobart supply agreement, with respect to Remoxy, will be assigned by PTI to King at a time mutually agreed to by the Parties, but no later than upon FDA approval of an NDA for
Remoxy. Except with King’s consent, not to be unreasonably withheld, the Mallinckrodt-Hobart supply agreement will have provisions such that the supply of Remoxy is independent of the supply of any other products covered by the agreement
(including provisions so that a breach by PTI of its obligations with respect to the other products will not affect the supply of Remoxy) and permit the assignment of the supply agreement with respect to Remoxy independent of any other products, it
being understood that King shall not withhold its consent to PTI’s entering into the Mallinckrodt-Hobart supply agreement if PTI agrees to indemnify King and hold King harmless with respect to damages which King may incur as a result of
Mallinckrodt-Hobart’s cross-termination of the supply agreement with respect to Remoxy as a result of a PTI’s breach of its obligations thereunder with respect to a product other than Remoxy. PTI will use commercially reasonable efforts to
have provisions of the type described in the preceding sentence included in the Mallinckrodt-Hobart supply agreement. 
 3.5.6
Except with respect to Remoxy, which is addressed by Section 3.5.5 above, King will have control and responsibility for the commercial supply of Products in the Territory. Except as provided for Remoxy in Sections 3.5.1, 3.5.2, and 3.5.5 above,
King may, in its sole discretion, decide to include its own manufacturing facility as a primary manufacturing site in the initial Regulatory Filings for any Products. Upon PTI’s request and with King’s consent (such consent not to be
unreasonably withheld), King agrees to enter into an agreement with respect to King’s commercial supply of Products to PTI or its licensee in Australia and New Zealand, the terms of such agreement to be negotiated in good faith. In the event
that King agrees to supply Product to PTI and PTI agrees to purchase Product from King for commercial supply in Australia and New Zealand, then such Product will be sold by King to PTI at King’s fully allocated cost plus ten percent (10%).


  
 9 








 3.5.7 Upon PTI’s written request, a second manufacturing site will be qualified for
each Product at such time as any of the following shall occur: (a) such Product reaches $250 million in annual Net Sales, or (b) there is an interruption of commercial supply, or (c) marketing in the applicable country of the
Territory so requires. With respect to Remoxy, such qualification will be obtained on a post-approval basis and may include, at King’s discretion, a King facility or other contract manufacturer. With respect to all other Products, if the
primary site for such Product is a King manufacturing site, PTI may require that the second manufacturing site not be a King manufacturing site. 
 3.5.8 In connection with the Manufacturing/CMC Plans, each Party 
 (a) will, upon
written request of the other Party, provide the other with the following documents to the extent that such documents being requested are available and in the possession or control of the Party to whom the request is made: for each Product,
pharmaceutics development report and history, copies of CMC section submitted as part of any Regulatory Filings, and minutes from any meeting or correspondence with any Regulatory Authority regarding pharmaceutics development or CMC; and 

(b) will allow the other Party to examine and copy, at the site where such records are normally stored and at a time that is mutually
acceptable to the Parties, the following: (i) CMC development protocols and reports, (ii) for each batch of API and each batch of Product produced as CTM, batch records, analytical monograph (tests and specifications), certificate of
analysis for Good Manufacturing Practices release, a table containing initial release and stability testing results (which table will be updated each time a stability pull point is analyzed), copies of any out of specification or laboratory
investigation report events, and report of any failed batches and any corrective action; and (iii) for each batch of Product produced as CTM, packaging and labeling batch records. 
 The Manufacturing/CMC Plans will include a list and brief description of protocols to be developed thereunder. The reports described in clause (a) above and the protocols in the Manufacturing/CMC
Plans that King notifies PTI that King would like to review will be developed in Consultation with the other Party and will be made available to the other Party in draft form with sufficient time for such Party to review and comment on the
foregoing, as well as being provided to the other Party in final form when such materials are completed. In addition, each Party will make available to the other Party such additional documentation reasonably related to such other Party’s
performance of its obligations hereunder that is in the possession or control of the Party to whom the request is made as such documentation is reasonably requested by the other Party. 

3.6 Yearly Brand Plans. King will prepare each Yearly Brand Plan for each Product and provide a copy to the JOC for its
review and comment. King, in Consultation with PTI, will have control and responsibility for Marketing each Product and for all matters under the Yearly Brand Plan, including determining the packaging, trade dress, and labeling (to the extent not
dictated by any applicable Regulatory Approval) for the distribution and sale of Product. Subject to Section 2.1.4 of the License Agreement, King shall use commercially reasonable efforts and diligence to Market the Product commensurate with
industry standards; provided that in no event shall such level of efforts and diligence be less than King uses in marketing its own products of similar market potential and at a similar stage in development as the applicable Product, taking into
account the competitiveness of the marketplace, the proprietary position of the Product, and the efforts and resources available to a company having a comparable market capitalization and taking into account then-current market conditions. King will
spend at least $10 million on Marketing for Remoxy in the U.S. Territory (excluding expenses related to a sales force) between the Closing Date and the date of Regulatory Approval of Remoxy by the FDA; provided that King will be entitled to suspend
such spending in the event the JOC decides to cease pursuing Regulatory Approval of Remoxy in the U.S. Territory, such suspension to only remain in effect until such time as the JOC elects to resume pursuing Regulatory Approval of Remoxy in the U.S.
Territory; provided further that King may propose changes in spending levels, with respect to which changes PTI will not unreasonably withhold its consent, in the event of (a) the FDA not accepting the NDA covering Remoxy for filing (or refusal
to file), (b) a determination by the FDA that such NDA is not approvable, or (c) a failure by the FDA to approve such NDA within eighteen (18) months of the date of the FDA’s acceptance of an NDA for Remoxy. 

  
 10 









 3.7 Collaboration Costs, Overruns, and Additional Expenditures. 

3.7.1 Subject to the terms and conditions of this Agreement, including Section 3.3.2, (a) all Collaboration Costs incurred by
either Party on and after the Closing Date shall be paid by King; and (b) all Collaboration Costs incurred by either Party on or after the Effective Date but prior to the Closing Date will be paid by King, with such payment not to be paid prior
to the Closing Date, so long as this Agreement is not terminated prior to Closing and such Collaboration Costs comply with the terms and conditions of this Agreement, as it will be in effect as of the Closing Date. Except as otherwise provided
herein, PTI shall be entitled to reimbursement for the Collaboration Costs incurred by it in connection with the Collaboration; provided that all such Collaboration Costs must be included in the budget governing the activities for which such costs
were incurred, subject to the provisions of this Section 3.7. All payments made by King hereunder shall be treated for all purposes, including all tax and accounting purposes, as the expenses of King and any applicable deductions shall be
wholly allocable to King. 
 3.7.2 The Parties understand and agree that a Product may generate new data or may be the subject
of new regulatory guidance at any time for any reason during a Calendar Year and that such changes may require substantial revisions to the clinical development activities associated with a Product or may cause PTI, in Consultation with King, or
Durect to re-work a Product. In the event either Party anticipates or becomes aware that the actual costs of any given task assigned to it may or will likely exceed the funds allocated to such task in the applicable Program Plan budget, such Party
shall promptly notify the JOC in writing. If the actual aggregate costs of conducting a particular Program Plan will likely exceed the aggregate annual funds budgeted for such Program Plan under the applicable Program Plan budget (or in the case of
work conducted under a Development Plan, if the actual aggregate costs of conducting a particular Development Plan will likely exceed 110% of the aggregate annual funds budgeted for such Development Plan under the applicable Development Plan
budget), the JOC shall work in good faith for up to thirty (30) days to approve a budget amendment that provides for the continued prompt clinical Development and Regulatory Approval of a Product. Such amendment may include increasing the
budget, readjusting the budget to allocate additional funds to such task, revising the scope of such task to permit satisfactory completion at the then-budgeted funding level, or all three. In the event no decision is reached, the matter shall be
subject to the arbitration provisions of Section 2.3.3 hereof. For purposes of clarity, neither Party shall be obligated to perform any additional services in connection with such task if the JOC does not approve increasing the budget to pay
for such additional services. 
 3.7.3 Notwithstanding the foregoing, either Party may, in its discretion, spend additional
amounts above and beyond those allocated in the applicable budget (“Discretionary Funding”) on any task assigned to such Party pursuant to the Program Plans or on any other task the JOC has approved. In such event, the Party wishing
to expend Discretionary Funding shall first inform the second Party of such first Party’s intent to do so. If the second Party consents to the Discretionary Funding being deemed a Collaboration Cost, which consent shall not be unreasonably
withheld, the Discretionary Funding shall constitute a Collaboration Cost. If the second Party does not consent, then the Discretionary Funding shall not constitute a Collaboration Cost, but shall be borne solely by the Party undertaking the
Discretionary Funding. 
 3.7.4 Except to the extent this Agreement expressly provides for payments that do not require JOC
approval, and except to the extent the JOC has approved any payment hereunder, neither Party shall (a) be obligated to incur any costs or expend any funds that have not been approved by such Party or (b) have the authority to cause the
other Party to incur any costs or expend any funds that have not been approved by such other Party. 
 3.8 Third Party
Licenses and Collaborations. Subject to the review and the approval of the JOC as provided in Section 2.2.5, King may enter into such other Third Party licenses and collaboration agreements as are reasonably necessary to accomplish the
objectives and purposes of the Development Program; and subject to the review and the approval of the JOC as provided in Section 2.2.5, PTI may enter into such Third Party licenses and collaborations agreements as are reasonably necessary to
accomplish the objectives and purposes of the Collaboration.Except with the other Party’s consent, not to be unreasonably withheld, each such agreement shall (a) if only one Party is a party to the agreement, name the other Party as a
third party beneficiary to such agreement, (b) include an assignment of all right, title, and interest in and to all work product and all inventions arising from the performance of such agreement, and all intellectual property rights attaching
thereto to the contracting Party, and (c) bind the relevant Third Party by obligations of confidentiality and non-use with respect to all such work product, inventions, and intellectual property rights that are at least as stringent as those
set forth herein. In order to ensure the ability of a Party (the “Non-Defaulting Party”) to proceed with the Development Program notwithstanding certain conduct of the other Party (the “Defaulting Party”) or the
termination of this Agreement by the Non-

  
 11 









 
Defaulting Party pursuant to Section 9.2.3, the JOC may require the inclusion, in those subcontracts, licenses, and other agreements (including manufacturing and supply agreements) entered
into in connection with the Development Program (“Third Party Agreements”) that are or are likely to become material to the conduct of the Development Program, of (i) an enforceable provision granting to the Non-Defaulting
Party hereto the same rights, benefits, and obligations as those granted to the Defaulting Party under that Third Party Agreement (whether by automatic assignment, a direct agreement, or otherwise), contingent upon a Default by the Defaulting Party
of that Third Party Agreement or the termination of this Agreement by the Non-Defaulting Party pursuant to Section 9.2.3, and (ii) the applicable Third-Party’s unconditional consent to such provision. 

3.9 Failure to Perform. 
 3.9.1 General. In the event that a Party does not perform a task or tasks assigned to it under a Program Plan, including due to a dispute as to the budget or scope of such task, or otherwise
fails to perform its Development or Marketing obligations hereunder, including meeting timelines and budgets set forth in the Program Plans, PTI and King will negotiate in good faith with respect to remedying such failures. In the event such
negotiations do not result in a resolution of such issues satisfactory to both Parties within thirty (30) days of the initiation of such negotiations, the matter shall be submitted to arbitration as set forth in Section 2.3.3. 

3.9.2 Remedy. In the event the arbitrators determine that the failure to perform was intentional or willful (but not as a
result of a failure to perform because of a disagreement about budget matters or regulatory strategy, which disagreement prevents the Parties from continuing to perform their obligations), the arbitrators may grant the non-breaching Party the right,
but not the obligation, to perform the task or tasks of the breaching Party. In addition, in the event of any breach, including a failure to use commercially reasonable efforts to perform a Party’s obligations, the arbitrators may award the
non-breaching Party monetary damages. 
 3.9.3 No Waiver. In the event a Party is granted a right to perform the
other Party’s task, a Party’s election to perform such task will not be deemed a waiver with respect to such electing Party’s ability to exercise any other rights hereunder, including any rights under Section 9.2.2 or 9.2.3.

  

	4.	INFORMATION EXCHANGE 

 4.1 Records. 
 4.1.1 Record Keeping. Each of PTI and
King shall maintain records in sufficient detail and in accordance with Good Laboratory Practice, Good Clinical Practice, and Good Manufacturing Practice, and as will properly reflect and document, in a manner appropriate for purposes of supporting
the filing of potential patent applications and Regulatory Filings, all work done and results achieved in the performance of the Development Program (including all data in the form required under any Applicable Law); provided, however, that prior to
King’s election to assume control and responsibility of execution of all matters under the Development Plan with respect to a particular Product, PTI shall be responsible for maintaining master files in accordance with Good Clinical Practices,
Good Laboratory Practices, and Good Manufacturing Practices, to the extent applicable; provided, further, that upon such election by King, PTI shall transfer such records to King with respect to such Product. Subject to Section 6.4.3hereof, PTI
and King each hereby grants the other the right to inspect and copy such records to the extent reasonably required for the performance of its obligations or exercise of its rights under this Agreement, and neither Party shall use such records or
information except to the extent otherwise permitted by this Agreement. 
 4.1.2 Reports. Each Party shall keep
the JOC reasonably informed about the status of the Development Program, including furnishing the JOC with copies of all material reports that relate to the Development Program. In particular, without limitation, each Party shall (a) provide
periodic reports in reasonable detail to the JOC, at least each Calendar Quarter and as requested from time to time by the JOC; (b) provide the other Party with access to all Technology and information employed in or arising out of the
Development Program solely for the purpose of conducting their respective roles hereunder; (c) provide the other Party with the information and reports described in Section 3.5.8 at least each Calendar Quarter and as requested from time to
time by the other Party; and (d) provide the other Party with information concerning the Development Program as such other Party shall reasonably request. For purposes hereof, “information” will include data, results, reports,
records, and similar information. 

  
 12 









 4.2 Updates; Adverse Event Information. 

4.2.1 Adverse Event Reports. In addition to the reports described in Section 4.1.2above, each Party shall provide the
JOC with all adverse event information and product complaint information required by such Party to be disclosed to any Regulatory Authority in connection with the Development, Marketing, or sale of any Product, within time frames consistent with
reporting obligations under Applicable Law. 
 4.2.2 Confidential Information. Except as otherwise required in
connection with disclosures to Regulatory Authorities required by Applicable Law, all reports, updates, adverse event, or product complaint and other information provided by a Party under this Agreement (including under this Section 4.2) shall
be considered Confidential Information of both Parties, regardless of who provided the same, and shall be subject to the terms of Article 8. 
 4.3 Sales Report. Starting immediately following the First Commercial Sale of a Product and for the Term of this Agreement, King, at its own expense, shall provide PTI with such U.S. sales
reports that King has obtained for itself from a third party vendor of King’s choice (such as IMS or NDC). Such report shall be provided to PTI on a timely basis in electronic form, if available, each Calendar Quarter and shall include no less
than the following data (provided that King has obtained or can obtain such data without undue burden): (a) Product sales by territory, by prescriber, and by strength, (b) Product sales by hospital, clinic, or mail-order services,
independent pharmacies, chains, mass merchandisers, and food stores, (c) a comparison of actual Product sales versus King’s forecast sales, (d) wholesale volume reports, (e) top 250 hospital report, and (f) a summary of
managed care accounts by volume of Product. In addition, starting immediately following the First Commercial Sale of a Product and for eighteen (18) months thereafter, King, at its own expense, shall (i) provide PTI with a weekly Product
sales report in electronic form and (ii) provide telephonic (or in-person) access to King’s national sales manager for purposes of holding an accurate discussion of a Product’s commercial sales trends, general market trends, and the
like. PTI agrees that all information, data, and reports provided by King to PTI hereunder shall be considered Confidential Information of King, subject to the requirements of Article 8. 

 

	5.	CERTAIN OTHER PROVISIONS 

 5.1 Product Liability Costs. The Parties understand and agree that, because of the nature of the collaborative effort set forth in this Agreement, should any Third Party claims be asserted
against either Party or both Parties or any of their Affiliates, agents, or representatives that are in the nature of product liability claims (“Claims”), the Parties will cooperate through the JOC to ensure that such claims are
defended and settled or compromised in a manner that best protects the interests of the Parties. In addition, the Parties will procure and maintain product liability insurance with first-class carriers in coverages and amounts and with deductibles
not less than those determined by the JOC; provided that: 
 (a) PTI shall obtain such insurance for a Product for Claims
arising prior to the Completion of Phase II, at PTI’s sole cost, which coverage shall continue until the earlier of (i) the initiation of Phase III for such Product and (ii) five years after the Completion of Phase II for such
Product; 
 (b) If Phase III for a Product is initiated, PTI shall obtain such insurance for such Product for Claims arising
following Completion of Phase II but prior to the First Commercial Sale of such Product, at PTI’s and King’s joint and equal cost, which coverage shall continue until the earlier of (i) the First Commercial Sale of such Product and
(ii) five years after the first to occur of (A) the completion of Phase III, (B) the decision of the JOC not to proceed with the commercial sale of such Product, and (C) the termination of this Agreement in its entirety pursuant
to Article 9 or with respect to such Product pursuant to Section 9.2.2(a), unless PTI or any of its Affiliates or its sublicensee continues to Develop the Product following such termination, in which case clause (d) below will apply;

 (c) As of the First Commercial Sale of a Product, King shall, at its sole cost, have obtained such insurance for a Product
for Claims arising following the First Commercial Sale of such Product, such insurance to be in an appropriate level (at a minimum of $50 million) exclusive of self-insured amounts and shall be in amounts maintained by King for other products of
King of similar market potential and at a similar stage in 

  
 13 









 
development as the applicable Product, taking into account any particular risks related to such Product, which coverage shall continue until the earlier of (i) the termination of this
Agreement in its entirety pursuant to Article 9 or with respect to such Product pursuant to Section 9.2.2(a), so long as PTI or any of its Affiliates or its sublicensee continues to sell the Product following such termination, and
(ii) five years after the last commercial sale of the Product pursuant to this Agreement; and 
 (d) PTI shall, at its
sole cost, obtain such insurance for a Product for Claims arising following the termination of this Agreement in its entirety or with respect to such Product, so long as PTI or any of its Affiliates or its sublicensee continues to Develop or sell
the Product following such termination, such insurance to be in an appropriate level (at a minimum of $50 million in the case of Marketed Products) exclusive of self-insured amounts and shall be in amounts maintained by PTI for other products of PTI
of similar market potential and at a similar stage in development as the applicable Product, taking into account any particular risks related to such Product, which coverage shall continue until five years after (i) termination of the
Development of such Product if PTI elects not to sell such Product commercially or (ii) the last commercial sale of the Product, as applicable. 
 The costs incurred to obtain the insurance described in this Section 5.1 shall not be deemed Collaboration Costs. The insurance described in this Section 5.1 shall name each Party as a
co-insured. 
 5.2 Product Packaging. The Parties agree that packaging and package inserts for each finished
Product sold to consumers will include King’s and PTI’s names and logos prominently displayed, subject to the approval of the applicable Regulatory Authorities. PTI agrees that it shall not use, and it will prohibit its Affiliates or
sublicensees from using, trademarks, trade dress (including product intaglio), packaging, or marketing material with respect to the Marketing of products in the Field in Australia and New Zealand that is confusingly similar with the Product
Trademarks and any Product trademarks, trade dress, packaging, or marketing material in the Territory, except with respect to the use of PTI’s name or logo. For clarity, PTI has the right to develop and market for use in Australia and New
Zealand the identical formula, including colorants and inks, and container-closure system, as is developed and marketed for each Product in the Territory; provided, however, that all secondary packaging components must be different. 

5.3 Mutual Financial Reporting. Each Party covenants to provide the other Party written notice at such time as
(a) such Party enters the “zone of insolvency,” as defined in Applicable Law, including interpretations in applicable case law, (b) such Party’s liabilities exceed its assets, (c) such Party is unable to pay its debts
as they become due, (d) there is an occurrence of a Default by such Party with respect to any of its debt or payment obligations or any agreement material to the Development Program, or (e) such Party suspends, closes, or otherwise ceases
to operate a majority of its business relating to this Agreement and the License Agreement. In addition, within 15 days of a written request of either Party (such request not to be made more than four times during any Calendar Year), the other Party
covenants to provide the requesting Party with its most recent audited financial reports. Each Party will treat all notices and financial reports (and the information contained therein) as Confidential Information of the other Party, subject to the
terms of Article 8. 
  

	6.	CLOSING; PAYMENTS 


6.1 Closing. 
 6.1.1 Covenants Pending Closing. 
 (a) Reasonable Efforts.
Subject to the terms and conditions of this Agreement, each of the Parties agrees to use all reasonable efforts to do, or cause to be done, all things necessary and appropriate to satisfy all conditions of and to consummate the transactions
contemplated by this Agreement, including the satisfaction of the applicable conditions set forth in Section 6.1.3 below. 

(b) Filings. The Parties shall cooperate with one another in the preparation, execution, and filing of all documents that are
required or permitted to be filed on or before the Closing, including filings pursuant to the HSR Act and will promptly file the same after the Effective Date. The related filing fees shall be borne by King, and the costs and expenses incurred by
each Party shall be paid by such Party. 

  
 14 









 6.1.2 Closing. As promptly as practicable after the Effective Date and after
the satisfaction by each Party or, if permissible, waiver of the conditions set forth in Sections 6.1.3(a) and (b), the Parties hereto shall cause the Closing to occur on the Closing Date. The Closing shall be held at the offices of Jones Day, 222
East 41st Street, New York, New York 10017, or such other place as the Parties shall agree, for the purpose of confirming the satisfaction or waiver, as the case may be, of the conditions set forth in Sections 6.1.3(a) and (b). If the Closing Date
has not occurred prior to February 9, 2006, either Party may terminate this Agreement upon written notice to the other Party; provided, however, that, as of such date, the Party terminating this Agreement is not in default under this Agreement.

 6.1.3 Conditions to Closing. 
 (a) The obligation of PTI to close shall be subject to the satisfaction on or before the Closing Date of the following conditions, any or all of which may be waived in whole or in part by PTI: 

(i) the expiration or termination of all applicable waiting periods under the HSR Act, unless a joint determination is
made by PTI and King (by certification from PTI and King to each other) that notification under the HSR Act is not required; 
 (ii) the representations and warranties made by King in Article 10 shall be true and correct in all material respects as of the Effective Date and as of the Closing Date with the same force and effect as
if they had been made as of the Closing Date, and King shall have performed all obligations and conditions herein required to be performed or observed by it on or prior to Closing; 

(iii) the provision by King to PTI of an officer’s certificate certifying that (i) and (ii) above are true
and correct as of the Closing Date; 
 (iv) the provision by King to PTI of an opinion of counsel, in form
reasonably satisfactory to PTI, that the execution of this Agreement and the License Agreement and the transactions contemplated hereby and thereby are duly authorized by all corporate action on the part of King; 

(v) the payment to PTI of the Program Fee by King; 

(vi) the execution by King and delivery to PTI of the License Agreement; and 

(vii) any agreement entered into by PTI with Mallinckrodt-Hobart pursuant to Section 3.5.5 shall be in form and
substance satisfactory to King. 
 (b) The obligation of King to close shall be subject to the satisfaction on or before the
Closing Date of the following conditions any or all of which may be waived in whole or in part by King: 
 (i)
the expiration or termination of all applicable waiting periods under the HSR Act, unless a joint determination is made by PTI and King (by certification from PTI and King to each other) that notification under the HSR Act is not required;

 (ii) the representations and warranties made by PTI in Article 10 shall be true and correct in all material
respects as of the Effective Date and as of the Closing Date with the same force and effect as if they had been made as of the Closing Date, and PTI shall have performed all obligations and conditions herein required to be performed or observed by
it on or prior to Closing; 
 (iii) the provision by PTI to King of an officer’s certificate certifying
that (i) and (ii) above are true and correct as of the Closing Date; 

  
 15 









 (iv) the provision by PTI to King of an opinion of counsel, in form
reasonably satisfactory to King, that the execution of this Agreement and the License Agreement and the transactions contemplated hereby and thereby are duly authorized by all corporate action on the part of PTI; 

(v) the execution by Durect and PTI of an agreement, in the form attached hereto as Exhibit B, granting
Durect’s consent to the transactions contemplated by this Agreement and the License Agreement; and 
 (vi)
the execution by PTI and delivery to King of the License Agreement. 
 6.2 Program Fee. Simultaneous with the
Closing, King shall pay to PTI a one-time collaboration fee in the amount of one hundred fifty million U.S. dollars ($150,000,000) (the “Program Fee”). The Program Fee shall be paid by King in U.S. dollars by wire to an account
designated by PTI. 
 6.3 Milestone Payments. 

6.3.1 Development Milestones. King will make the following payments to PTI within ten (10) days after the
determination of the first achievement of each of the milestones set forth below. For purposes of clarity, it is understood and agreed that the following milestone payments shall (a) be non-refundable and non-creditable and (b) only be
payable once with respect to each Product, such that that a payment will be due only once for (i) each Product with a given active opioid, but will not be payable with respect to line extensions, new indications, new dosages, or new Regulatory
Filings that subsequently may be filed for a Product that contains the same active opioid, and (ii) the first filing of an IND or NDA or the first regulatory approvable letter for such Product in a country of the Territory, notwithstanding the
subsequent filing or approval of other Regulatory Filings in other countries in the Territory for a Product with the same active opioid. 
  

									
	 	  	Payment	 
	 Milestone
	  	Remoxy	 	  	All Other Products	 
	 Acceptance by a Regulatory Authority of the first IND filing for a Product in the Territory
	  	 	N/A	  	  	$	5 Million	  
	 Acceptance by a Regulatory Authority of the first NDA filing for a Product in the Territory
	  	$	15 Million	  	  	$	15 Million	  
	 First regulatory approvable letter transmitted by a Regulatory Authority for NDA of a Product in the Territory
	  	$	15 Million	  	  	$	20 Million	  
	 Total Development Milestones for Each Product
	  	$	30 Million	  	  	$	40 Million	  

 6.3.2 Termination of Milestones. In the event any suit, action, or proceeding results in
the entry of an injunction pursuant to Section 4.6 of the License Agreement that prevents King from Marketing a Product, which injunction is unappealable or unappealed within the time allowed for appeal, King’s obligation to make milestone
payments with respect to future milestones for such Product pursuant to this Section 6.3 shall immediately terminate. It is understood and agreed that following the issuance of any such injunction, PTI’s Development and manufacturing
obligations with respect to such Product shall be waived, and the Parties shall promptly amend the Project Plans and, if required to meet the minimum obligations under Section 3.1.3, designate a replacement Product pursuant to
Section 3.1.2. For purposes of clarity, it is understood that this Section 6.3.2 shall not relieve King of its obligation to pay any milestone payments for milestones that were achieved prior to the date such injunction is issued or to
subsequently pay milestones in the event such injunction is lifted. 

  
 16 









 6.4 Collaboration Costs. 

6.4.1 Determination of Collaboration Costs. Within ten (10) days following the end of the second month of each
Calendar Quarter, PTI shall submit to King a documented and reasonably detailed accounting of all Collaboration Costs, determined in accordance with GAAP, incurred by PTI with respect to all Products during the last month of the prior Calendar
Quarter and the first two (2) months of the current Calendar Quarter, which King shall pay to PTI pursuant to Section 3.7 above. All such payments shall be made within thirty (30) days following the end of the second month of the
applicable Calendar Quarter. 
 6.4.2 Currency Conversion. All Collaboration Costs incurred in currencies other
than U.S. dollars shall be converted to U.S. dollars using the method agreed by the Parties and set forth in the budget of the applicable Program Plan. 
 6.4.3 Records. Each Party shall maintain its records in accordance with GAAP. PTI shall maintain, and shall require that its Affiliates, Sublicensees, and licensees maintain, for three years
from the date of each quarterly reconciliation of Collaboration Costs, complete and accurate records of the same, in sufficient detail to allow calculation and verification of Collaboration Costs. King shall have the right for a period of three
years after receiving any report or statement with respect to Collaboration Costs to appoint, at its expense, an independent certified public accountant reasonably acceptable to PTI to inspect the relevant records of PTI and its Affiliates and, if
applicable, Sublicensees to verify such report or statement. PTI, its Affiliates, and, if applicable, Sublicensees shall each make its records available for inspection by such independent certified public accountant (who agrees to confidentiality
provisions consistent with Article 8) during regular business hours at such place or places where such records are customarily kept, upon reasonable notice from King, solely to verify the accuracy of the reports and payments. PTI will use
commercially reasonable efforts to ensure that King is granted the right to audit PTI’s Sublicensees’ financial records, as provided herein; provided that, to the extent that PTI does not obtain that right for King, PTI shall obtain for
itself such right and, at the request of King, PTI shall exercise such audit right with respect to such Sublicensees and provide the results of such audit for inspection by King pursuant to this Section 6.4.3. Such inspection right shall not be
exercised more than once in any Calendar Year. The results of each inspection, if any, shall be binding on both Parties. In the event that any such inspection shall conclude that Collaboration Costs were overstated by more than five percent
(5%) in any given Calendar Year, PTI shall pay for all the reasonable costs of King in respect of the inspection, as well as make any payments required to remedy the overstatement. Any dispute regarding the results of any such inspection
hereunder shall be subject to the dispute resolution provisions of Section 2.3 hereof; provided that if PTI is the Party with final decision-making authority over the subject matter in dispute, and the CEO’s are unable to reach agreement
even after good faith discussions in accordance with Section 2.3, then the dispute shall not be subject to the sole discretion of either Party but shall be subject to arbitration pursuant to the provisions of Section 2.3.3. All information
and data reviewed in the inspection shall be used only for the purpose of verifying the accuracy of the reports and payments and shall be treated as PTI’s Confidential Information subject to the obligations of this Agreement. 

6.4.4 Overdue Payments. All overdue payments, not subject to a bona fide dispute, due and payable pursuant to this
Agreement shall bear interest at a rate of 1% per month from the due date until paid in full. 
 6.4.5 Withholding
Taxes. All payments made by a Party hereunder shall be made to the other Party free and clear of any Taxes. If a Party is required by law to deduct or withhold any Taxes from any payment made hereunder, then such Party shall (a) make
such deductions and withholdings; (b) pay the full amount deducted or withheld to the relevant taxing authority or other applicable governmental authority; and (c) promptly provide the other Party with written documentation of any such
payment that, if applicable, shall be in a form sufficient to satisfy the requirements of the United States Internal Revenue Code relating to a claim by such other Party for a foreign tax credit in respect of such Tax payment. 

 

	7.	LIMITATIONS 

 7.1
For PTI. Except as otherwise expressly permitted herein or in the License Agreement with respect to Crain/Shen SABER Drugs, during the Term, PTI agrees that it will not develop or market any products in the Field in the Territory on
its own or with or through an Affiliate, Sublicensee, licensee, or other Third Party, or grant to any Affiliate, Sublicensee, licensee, or other Third Party any right, option, license, covenant not to sue, or any other agreement to forbear from
enforcing PTI’s rights to do so. 

  
 17 









 7.2 For King. Except as otherwise expressly permitted herein or in the License
Agreement with respect to Products, during the Term, King agrees that it will not develop or market any products incorporating SABER Technology in the Territory with Durect or license from Durect or any licensee or other recipient of rights from
Durect, any rights to develop or market any such products, except any rights for use in the Collaboration, in each case, either on its own or with or through an Affiliate, Sublicensee, licensee, or other Third Party. 

 

	8.	TREATMENT OF CONFIDENTIAL INFORMATION; PUBLICITY. 

 8.1 Confidentiality. 
 8.1.1 Confidentiality
Obligations. PTI and King each acknowledges and agrees that the other Party’s Confidential Information constitutes highly valuable and proprietary confidential information and materials. PTI and King each agrees that during the Term of
this Agreement and for an additional five years (or, in the case of any Confidential Information identified as a trade secret by the Disclosing Party at the time of disclosure, for so long as such trade secret Confidential Information is susceptible
of remaining a trade secret), it will use commercially reasonable efforts to keep confidential, and will use commercially reasonable efforts to cause its employees, Consultants, Affiliates, agents, advisors, and Sublicensees to keep confidential,
all Confidential Information of the other Party. Neither PTI nor King nor any of their respective employees, Consultants, Affiliates, or Sublicensees shall use Confidential Information of the other Party for any purpose whatsoever except as
expressly permitted in this Agreement or the License Agreement. 
 8.1.2 Limited Disclosure. PTI and King each
agree that any disclosure of the other Party’s Confidential Information to any officer, employee, Consultant, agent, or Affiliate of PTI or King, as the case may be, shall be made only if and to the extent necessary to carry out its rights and
responsibilities under this Agreement and the License Agreement, shall be limited to the maximum extent possible consistent with such rights and responsibilities, and shall only be made to persons who are bound by written confidentiality obligations
to maintain the confidentiality thereof and not to use such Confidential Information except as expressly permitted by this Agreement or the License Agreement. PTI and King each further agrees not to disclose or transfer the other Party’s
Confidential Information to any Third Parties under any circumstance without the prior written approval from the other Party (such approval not to be unreasonably withheld), except as otherwise required by law, and except as otherwise expressly
permitted by this Agreement or the License Agreement. Each Party shall take such action, and shall cause its Affiliates and Sublicensees to take such action, to preserve the confidentiality of the Disclosing Party’s Confidential Information as
the Receiving Party would customarily take to preserve the confidentiality of its own Confidential Information, using a level of care that shall not under any circumstances be less than reasonable and prudent care. If a court or other government
authority orders that the Receiving Party disclose Confidential Information, or proposes such an order, the Receiving Party must notify the Disclosing Party immediately after learning of the order, so as to provide the Disclosing Party an
opportunity to protect the information, and the Receiving Party must limit the disclosure to the minimum that will comply with the order. Each Party, upon the request of the other Party, will return all the Confidential Information disclosed or
transferred to it by the other Party pursuant to this Agreement, including all copies and extracts of documents and all manifestations in whatever form, within 60 days of the request or, if earlier, the termination or expiration of this Agreement;
provided however, that a Party may retain Confidential Information of the other Party relating to any license or right to use Technology that survives such termination and one copy of all other Confidential Information may be retained in inactive
archives solely for the purpose of establishing the contents thereof. 
 8.1.3 Employees and Consultants. PTI and
King each hereby agrees that all of its employees, and all of the employees of its Affiliates, and any Consultants to such Party or its Affiliates, in any case that participate in the activities of the Development Program and who shall have access
to Confidential Information of the other Party shall be bound by written obligations to maintain the same in confidence and not to use such information except as expressly permitted herein. Each Party agrees to enforce confidentiality obligations to
which its employees and Consultants (and those of its Affiliates) are obligated. Each Party agrees to have each employee or Consultant that participates in the Development Program enter into a written agreement with such Party that includes an
assignment to such Party of all right, title, and interest in and to all work product and all inventions arising during the course of his or her employment with or provision of services to such Party, and all intellectual property rights attaching
thereto. 

  
 18 









 8.1.4 Equitable Relief. PTI and King each acknowledges that a breach by it of
Article 7 or the provisions of this Article 8 cannot reasonably or adequately be compensated in damages in an action at law and that such a breach may cause the other Party irreparable injury and damage. By reason thereof, each Party agrees that the
other Party may be entitled, in addition to any other remedies it may have under this Agreement or otherwise, to preliminary and permanent injunctive and other equitable relief to prevent or curtail any breach of Article 7 or 8 by the other Party;
provided, however, that no specification in this Agreement of a specific legal or equitable remedy shall be construed as a waiver or prohibition against the pursuing of other legal or equitable remedies in the event of such a breach. Each Party
agrees that the existence of any claim, demand, or cause of action of it against the other Party, whether predicated upon this Agreement, or otherwise, shall not constitute a defense to the enforcement by the other Party, or its successors or
assigns, of the covenants contained in Articles 7 and 8. 
 8.2 Publicity. Neither Party may publicly disclose the
existence or terms of this Agreement without the prior written consent of the other Party. Notwithstanding the foregoing, each Party shall have the right to disclose the existence or terms of this Agreement, or information relating to the
Development Program, Remoxy, or other Products, without the consent of the other Party (a) to the extent the disclosure is required by law or by the requirements of any nationally recognized securities exchange, quotation system, or
over-the-counter market on which such Party has its securities listed or traded, (b) to any investors, prospective investors, lenders, and other potential financing sources who are obligated to keep such information confidential, or (c) to
any Third Party who is obligated by written confidentiality agreement to keep such information confidential; provided, in each case, that the Party making such disclosure shall use reasonable efforts to provide the other Party with as much notice
beforehand as is reasonable under the circumstances with respect to any such disclosure. The Parties, upon the execution of this Agreement, will mutually agree to a press release with respect to the Development Program for publication. Once such
press release or any other written statement is approved for disclosure by both Parties, either Party may make subsequent public disclosure of the contents of such statement without the further approval of the other Party. Additionally from
time-to-time PTI may wish to issue press releases or make similar disclosures regarding the results or status of its research or Product activities, the achievement of a regulatory or development milestone, or any other material achievements under
this Agreement or the DLA. Notwithstanding anything to the contrary in Section 8.3 or this Section 8.2, PTI shall be free to issue such press releases or make such disclosures, and shall have the right to choose the wording and timing of
any such press releases and disclosures; provided that PTI agrees to provide King a draft copy of any such press release or disclosure at least twelve (12) hours prior to its publication or disclosure, which copy in any event must be provided
during normal business hours, and provided further that such disclosure does not mention King without King’s prior written consent. King shall have the right to inform PTI of any information contained therein that King believes is inaccurate.

 8.3 Publication. It is expected that each Party may wish to publish the results of its research under this
Agreement and the DLA in scientific journals or through scientific conferences, which disclosures will be subject to the obligations of this Section 8.3. At any time prior to the filing of an NDA for a particular Product, PTI may publish the
results of its research for such Product in scientific journals or through scientific conferences; provided that PTI complies with the provisions of this Section 8.3; and provided further that such publication does not mention King without
King’s prior written consent. At any time following the filing of an NDA for a particular Product, King may publish the results of its research for such Product in scientific journals or through scientific conferences; provided that King
complies with the provisions of this Section 8.3; and provided further that such publication does not mention PTI without PTI’s prior written consent. In order to safeguard patent rights and other intellectual property, the Party wishing
to publish in any scientific journal or at any scientific conference the results of any research being conducted by the Parties in the Development Program shall first submit a draft of each proposed technical publication or an outline of each
proposed presentation for a scientific conference, with any related materials to be published or distributed in connection therewith, to the other Party for review, comment, and consideration of appropriate patent action at least thirty
(30) days prior to any submission for publication (or in the case of a disclosure in connection with a scientific conference, at least fifteen (15) days prior to such disclosure). Within fifteen (15) days of receipt of the
prepublication materials (or as soon as practicable in connection with an outline of an oral presentation), the other Party will notify the Party seeking publication as to whether a patent application shall be prepared and filed (in which case the
Party seeking publication shall delay submission until the first to occur of the filing of a patent application and thirty (30) days from such notice provided by the JOC) or whether such publication must be revised to eliminate Confidential
Information of a Party (in which case the Party seeking publication shall delete from any proposed publication all such Confidential Information contained therein). 

  
 19 










	9.	TERM AND TERMINATION 

 9.1 Term. This Agreement shall commence on the Closing Date and shall continue in full force and effect until the later of (a) the expiration of the last to expire of any Patent Rights
licensed under the License Agreement or developed in the Collaboration and (b) the expiration of all periods of market exclusivity relating to any Products in the Territory, unless earlier terminated in accordance with the provisions of
Section 6.1.2 or this Article 9(the “Term”). 
 9.2 Termination. This Agreement may be
terminated, with respect to a particular Product or in whole, as follows: 
 9.2.1 Mutual Termination. The Parties
may agree in writing to mutually terminate this Agreement at any time. If a Party has given notice of termination of this Agreement pursuant to Section 9.2.2, 9.2.3, or 9.2.4 hereof, the other Party may not invoke this Section 9.2.1 by
agreeing to such termination. In the event of termination pursuant to this Section 9.2.1, the Parties shall negotiate in good faith within thirty (30) days after the date of such termination the terms and conditions of such termination. In
addition, King shall make payments due and payable for the Final Calendar Year as required by Sections 6.3 and 6.4, as well as pay any other amounts due and owing on the date of termination. 

9.2.2 Termination At Will. 
 (a) Product Specific Termination. King may terminate this Agreement with respect to a particular Product as set forth in Section 3.1.4 above. In connection with a termination pursuant to this
Section 9.2.2(a), the following shall apply: 
 (i) King shall execute and deliver to PTI such documents,
material, data, records, analyses, and information and do such things as reasonably requested by PTI to the extent reasonably related to the Development and Marketing of such Terminated Product in the Territory, including the following, in each case
to the extent so related: (A) King shall use its commercially reasonable efforts to effect a reasonably smooth and orderly transition of any ongoing clinical studies, Regulatory Approval, or pre-marketing efforts to PTI (including all data and
reports in the possession of King) with respect to the Terminated Product, including the assignment of any relevant Third Party contracts and Regulatory Filings and, unless otherwise requested by PTI, shall use commercially reasonable efforts to
cancel all cancelable costs already incurred and mitigate all other costs incurred in connection with the Development Program for such Terminated Product; (B) King shall make its personnel and other resources reasonably available to PTI as
reasonably necessary to effect a reasonably orderly transition of development responsibilities for such Terminated Product; (C) King shall pay all non-cancelable costs in connection with the Development Program for such Terminated Product;
(D) King shall pay all costs of any of the ongoing clinical trials of such Terminated Product for a period of six (6) months from the effective date of termination, but only for such costs incurred for those patients already enrolled in
the study at the time of giving the termination notice (it being understood that King shall continue to be liable beyond the end of such six (6)-month period for any non-cancelable costs associated with such clinical trials); (E) all rights and
licenses granted herein to King with respect to the Terminated Product shall, for no additional consideration, immediately terminate; and (F) King shall, within ten (10) days after the termination date, provide and assign to PTI all
clinical data, INDs, NDAs, Regulatory Approvals, Regulatory Filings, and all other documentation reasonably useful in respect of the Terminated Product in the Territory. Except as otherwise provided herein, all reasonable costs and expenses incurred
with respect to the foregoing (except for non-cancelable costs as described in clause (C) above) will be borne by King for a period of six (6) months after the effective date of termination, unless the Parties otherwise agree. 

  
 20 









 (ii) The Parties shall make payments due and payable for the Final Calendar
Year with respect to the Terminated Product as required by Sections 6.3 and 6.4, as well as pay any other amounts due and owing on the date of termination. 
 (b) Termination of the Agreement in its Entirety. King may terminate this Agreement in its entirety upon six (6) months’ prior written notice to PTI, which notice may be given
(1) following the third anniversary of the Effective Date, or (2) in the event of Scientific Failure, with such termination to be effective at the end of such six (6)-month period. As used herein, “Scientific Failure”
means a determination by the JOC that the Development Program is unlikely to be commercially viable, or is unlikely to generate any marketable Products, as determined in accordance with its business, legal, medical, and scientific judgment. In
connection with a termination pursuant to this Section 9.2.2(b), the following shall apply: 
 (i) King
shall execute and deliver to PTI such documents, material, data, records, analyses, and information and do such things as reasonably requested by PTI to the extent reasonably related to the Development and Marketing of all Products in the Territory,
including the following, in each case only to the extent so related: (A) King shall use its commercially reasonable efforts to effect a reasonably smooth and orderly transition of any ongoing clinical studies, Regulatory Approval, or
pre-marketing efforts to PTI (including all data and reports in the possession of King) with respect to the Products, including the assignment of any relevant Third Party contracts and Regulatory Filings and, unless otherwise requested by PTI, shall
use commercially reasonable efforts to cancel all cancelable costs already incurred and mitigate all other costs incurred in connection with the Development Program for all Products; (B) King shall make its personnel and other resources
reasonably available to PTI as reasonably necessary to effect a reasonably orderly transition of development responsibilities for such Products; (C) King shall pay all non-cancelable costs in connection with the Development Program for such
Products; (D) King shall pay all costs of any of the ongoing clinical trials of such Products for a period of six (6) months from the effective date of termination, but only for such costs incurred for those patients already enrolled in
the study at the time of giving the termination notice (it being understood that King shall continue to be liable beyond the end of such six (6)-month period for any non-cancelable costs associated with such clinical trials); (E) all rights and
licenses granted herein to King with respect to the Products shall, for no additional consideration, immediately terminate; and (F) King shall, within ten (10) days after the termination date, provide and assign to PTI all clinical data,
INDs, NDAs, Regulatory Approvals, Regulatory Filings, and all other documentation reasonably useful in respect of the Products in the Territory. All reasonable costs and expenses incurred with respect to the foregoing (except for non-cancelable
costs as described in clause (C) above) will be borne by King for a period of six (6) months after the effective date of termination, unless the Parties otherwise agree. In addition, King shall continue to pay the labor costs of PTI
personnel at the FTE Rate for the number of hours of service called for in the budget then in effect, whether or not such PTI employees are providing such services, for a period of six (6) months after the effective date of termination;
provided that, if a budget is not in effect for a portion of such six (6)-month period, the labor costs for such unbudgeted period will be paid for the number of hours of service set forth in the final approved budget pro-rated to the length of such
unbudgeted period. Notwithstanding the foregoing, King shall not be obligated to continue to pay such labor costs for such PTI personnel to the extent such PTI personnel are actually redeployed to other projects funded by a Third Party or are no
longer employed by PTI. 
 (ii) The Parties shall make payments due and payable for the Final Calendar Year with
respect to the Products as required by Sections 6.3 and 6.4, as well as pay any other amounts due and owing on the date of termination. 
 9.2.3 Termination for Material Breach. In the event that either Party breaches any material term of this Agreement that applies to it, the other Party shall have the right to terminate this
Agreement by giving sixty (60) days’ prior written notice to the breaching Party; provided, however, that in the case of a breach capable of being cured, if the breaching Party shall cure the breach within such notice period after notice
shall have been given, then such notice shall not be effective. For purposes of this Section 9.2.3, (i) the failure to timely make any payment or fulfill any funding obligation under this Agreement that is not subject to a bona fide
dispute and (ii) the commission of any act or the occurrence of any omission, in each case that constitutes a breach of any material term of this Agreement shall each constitute a material breach of this Agreement (but the list set forth in
clauses (i) and (ii) shall not be deemed an exhaustive list of material breaches of this Agreement). In the event of a termination pursuant to this Section 9.2.3, the following shall apply (the “Termination
Procedures”): 

  
 21 









 (a) In the event that PTI is the breaching Party, King shall execute and deliver to PTI
such documents, material, data, records, analyses, and information and do such things as reasonably requested by PTI to the extent reasonably related to the Development and Marketing of the Products in the Territory, including the following, in each
case to the extent so related: (i) King shall use its commercially reasonable efforts to effect a reasonably smooth and orderly transition of any ongoing clinical studies, Regulatory Approval, or pre-marketing efforts to PTI with respect to the
Products (including all data and reports in the possession of King), including the assignment of any relevant Third Party contracts and Regulatory Filings and, unless otherwise requested by PTI, use commercially reasonable efforts to cancel all
cancelable costs already incurred and mitigate all other costs incurred in connection with the Development Program; (ii) King shall make its personnel and other resources reasonably available to PTI as reasonably necessary to effect a
reasonably orderly transition of development responsibilities for the Products; (iii) all rights and licenses granted herein to King with respect to the Products shall, for no additional consideration, immediately terminate; and (iv) King
shall, within 10 days after the termination date, provide and assign to PTI all clinical data, INDs, NDAs, Regulatory Approvals, Regulatory Filings, and all other documentation reasonably useful in respect of the Products in the Territory. Except as
otherwise provided herein, all reasonable costs and expenses incurred with respect to the foregoing will be borne by PTI, unless the Parties otherwise agree. 
 (b) In the event that King is the breaching Party, King shall execute and deliver to PTI such documents, material, data, records, analyses, and information and do such things as reasonably requested by
PTI to the extent reasonably related to the Development and Marketing of the Products in the Territory, including the following, in each case to the extent so related: (i) King shall use its commercially reasonable efforts to effect a
reasonably smooth and orderly transition of any ongoing clinical studies, Regulatory Approval, or pre-marketing efforts to PTI with respect to the Products (including all data and reports in the possession of King), including the assignment of any
relevant Third Party contracts and Regulatory Filings and, unless otherwise requested by PTI, use commercially reasonable efforts to cancel all cancelable costs already incurred and mitigate all other costs incurred in connection with the
Development Program; (ii) King shall make its personnel and other resources reasonably available to PTI as reasonably necessary to effect a reasonably orderly transition of development responsibilities for the Products; (iii) King shall
pay all the costs for the completion of any of the ongoing clinical trials of Products, but only for such costs directly incurred for those patients already enrolled in the study at the time of giving the termination notice, as well as all other
non-cancelable costs in connection with the Development Program for the Products; (iv) all rights and licenses granted herein to King with respect to the Products shall, for no additional consideration, immediately terminate; and (v) King
shall, within 10 days after the termination date, provide and assign to PTI all clinical data, INDs, NDAs, Regulatory Approvals, Regulatory Filings, and all other documentation reasonably useful in respect of the Products in the Territory. Except as
otherwise provided herein, all reasonable costs and expenses incurred with respect to the foregoing will be borne by King, unless the Parties otherwise agree. In addition, King shall continue to pay the labor costs of PTI personnel at the FTE Rate
for the number of hours of service called for in the budget then in effect, whether or not such PTI employees are providing such services, for a period of six (6) months after the effective date of termination; provided that, if a budget is not
in effect for a portion of such six (6)-month period, the labor costs for such unbudgeted period will be paid for the number of hours of service set forth in the final approved budget pro-rated to the length of such unbudgeted period.
Notwithstanding the foregoing, King shall not be obligated to continue to pay such labor costs for such PTI personnel to the extent such PTI personnel are actually redeployed to other projects funded by a Third Party or are no longer employed by
PTI. 
 (c) The Parties shall make payments due and payable for the Final Calendar Year as required by Sections 6.3 and 6.4, as
well as pay any other amounts due and owing on the date of termination. 
 9.2.4 Termination for Insolvency. In
the event that a Party (a) makes an assignment for the benefit of creditors, (b) appoints or suffers appointment of a receiver or trustee over its property, (c) is generally unable to pay its debts as they become due, (d) files a
petition under, or invokes the protection of, any bankruptcy, insolvency, or similar laws, and consent is requested but not granted for an assignment of 

  
 22 









 
the Agreement under Section 9.4.1(c) hereof, (e) has a petition or proceeding filed against it under any bankruptcy, insolvency, or similar laws, which is not dismissed within sixty
(60) days, and consent is requested but not granted for an assignment of the Agreement under Section 9.4.1(c) hereof, or (f) suspends, closes, or otherwise ceases to operate a majority of its business relating to this Agreement and
the License Agreement, then the other Party may terminate this Agreement effective immediately upon written notice to the first Party. In the event of a termination pursuant to this Section 9.2.4, the Termination Procedures shall apply, with
the terminating Party treated as the non-breaching Party. Nothing in this Section 9.2.4 limits or affects any other rights, elections, or remedies that the terminating Party may have under the Bankruptcy Code, or other Applicable Law and all
such rights, elections, and remedies are expressly reserved. 
 9.2.5 Required Assignments. If a Party is required
by the terms of this Agreement to assign or transfer to the other Party any agreement, document, or right and such Party, after utilizing the level of efforts required hereunder, is unable to do so as the result of forces beyond its reasonable
control, then the Party shall use its commercially reasonable efforts to make available to the other Party the material benefits of such agreement, document, or right in lieu of such assignment or transfer. 

9.3 Surviving Provisions. Termination and expiration of this Agreement for any reason shall be without prejudice to:

 (a) the following provisions, which shall survive termination or expiration of this Agreement for as long as necessary to
permit their full discharge: Sections 5.1, 6.4.3, 8.1, 11.1, 11.2, 11.3, 11.5 and 11.6; Sections 9.2.2(b)(i) and 9.2.2(b)(ii) in the event of a termination by King pursuant to Section 9.2.2(b); Sections 9.2.3(b) and 9.2.3(c) in
the event of a termination by PTI pursuant to Section 9.2.3, 9.2.4 or 9.4.3; Sections 9.2.3(a) and 9.2.3(c) in the event of a termination by King pursuant to Section 9.2.3, 9.2.4 or 9.4.3; the obligations of the Parties set forth in
the first two sentences of Section 8.2; Articles 12 and 13; and the definitions set forth in Annex A; additionally, in the event of termination of this Agreement for any reason, King’s reporting obligations under
Section 4.2.1 with respect to adverse event information and product complaint information shall survive; provided that King shall provide such information directly to the PTI rather than to the JOC, and 

(b) any other rights or remedies provided at law or equity that either Party may otherwise have against the other. Except as otherwise
provided in this Section 9.3, all rights and obligations of the Parties under this Agreement shall terminate upon the expiration or termination of this Agreement; provided that it is expressly understood that nothing herein shall relieve any
Party from liability from any breach of any covenant or agreement of such Party contained herein or any willful or intentional breach of any representation or warranty of such Party contained herein. 

9.4 Treatment Upon Bankruptcy. 
 9.4.1 Assumption and Assignment of Agreement. 
 (a) Notwithstanding
any other provision of this Agreement, the License Agreement, or any other related agreements, each Party hereby consents to the assumption of this Agreement by the other Party (the “Debtor Party”) in any case commenced by or
against the Debtor Party under the Bankruptcy Code to the extent that such consent is required under Section 365(c)(1) of the Bankruptcy Code, but only if the Debtor Party is otherwise entitled to assume this Agreement under the applicable
requirements of the Bankruptcy Code. The sole purpose of the foregoing consent is to overcome any restriction potentially imposed by Section 365(c)(1) of the Bankruptcy Code on the Debtor Party’s assumption of this Agreement in a
bankruptcy case concerning the Debtor Party. It is not intended to limit any other rights of the other Party (the “Non-Debtor Party”) under this Agreement or any provision of the Bankruptcy Code, including Section 365(c)(1).
The foregoing consent applies only to the assumption of this Agreement by the Debtor Party and does not apply to the Debtor Party’s assignment of this Agreement or any rights hereunder to a Third Party. 

(b) Notwithstanding any other provision of this Agreement (including Sections 9.4.1(c) and 13.9), the License Agreement, or any other
related agreements, the Non-Debtor Party hereby consents to the assignment of this Agreement by the Debtor Party to a Third Party solely in connection with a sale of all or substantially all of the Debtor Party’s business or assets relating to
this Agreement and the License Agreement to such Third Party, pursuant to an orderly sale process under Section 363 of the Bankruptcy Code or a confirmed plan 

  
 23 









 
under Section 1129 of the Bankruptcy Code, that contemplates the continued operation of the purchased business or assets and, if PTI is the Debtor Party, the retention of the Existing
Management Team, provided that such Third Party promptly agrees in writing to be bound by the terms and conditions of this Agreement and the Debtor Party is otherwise entitled to assign this Agreement under the applicable requirements of the
Bankruptcy Code. The sole purpose of the foregoing consent is to overcome any restriction potentially imposed by Section 365(c)(1) of the Bankruptcy Code on the Debtor Party’s assignment of this Agreement under the specific circumstances
described in this Section 9.4.1(b). It is not intended to limit any other rights of the Non-Debtor Party under this Agreement or any provision of the Bankruptcy Code, including Section 365(c)(1), or to apply to the assignment of this
Agreement in any other context. 
 (c) Notwithstanding any other provision of this Agreement (including Section 13.9), the
License Agreement, or any other related agreements, but subject to Section 9.4.1(b) above, the Debtor Party may only assign this Agreement to a Third Party in any case commenced by or against it under the Bankruptcy Code with the prior written
consent of the Non-Debtor Party. 
 9.4.2 Intellectual Property Rights. All rights related to and licenses of
intellectual property granted under this Agreement and the License Agreement by one Party to the other Party are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to
“intellectual property” as defined under Section 101(35A) of the Bankruptcy Code. In addition to any other rights, elections, and remedies under this Agreement, any related agreements, the Bankruptcy Code, or any other Applicable Law,
upon a written request under Section 365(n) of the Bankruptcy Code, the Non-Debtor Party shall be entitled to complete access to any intellectual property of the Debtor Party pertaining to the rights granted in the licenses under the License
Agreement, all embodiments of such intellectual property and all documents, material, data, records, analyses, and information related thereto (including all clinical data, INDs, NDAs, Regulatory Approvals, Regulatory Filings, and all other
documentation reasonably useful in respect of Product in the Territory in the Field). This Agreement and any other related agreements (to the extent such agreements do not constitute licenses of intellectual property under the Bankruptcy Code) shall
be considered agreements supplementary (as such term is used in Section 365(n) of the Bankruptcy Code) to the License Agreement and any other intellectual property licenses between the Parties. 

9.4.3 Rejection in Bankruptcy. Any rejection of this Agreement by the Debtor Party pursuant to Section 365 of the
Bankruptcy Code shall constitute a material breach of this Agreement not subject to notice or cure. Upon any such rejection, (a) all rights, elections, and remedies of the Non-Debtor Party to this Agreement (including under Section 365 of
the Bankruptcy Code) are expressly reserved, and (b) in the event that this Agreement is deemed terminated upon or subsequent to such rejection, the Termination Procedures shall apply, with the Non-Debtor Party treated as the non-breaching
Party. Further, upon any such rejection, the Parties intend and agree that the Non-Debtor Party may elect to retain its rights under this Agreement pursuant to Section 365(n) of the Bankruptcy Code and that such election shall, among other
things, entitle the Non-Debtor Party to invoke and exercise all of its rights to any intellectual property under this Agreement, the License Agreement, and any other related agreements. 

9.5 Damages; Relief. Termination of this Agreement shall not preclude any Party from claiming any other damages,
compensation, or legal or equitable relief that it may be entitled to upon such termination. 
 9.6 Tax Treatment.
The Parties intend that, for United States federal income tax purposes and all other applicable state, local, and foreign income or franchise taxes as may be permitted by law, the Collaboration shall be treated as a cost sharing arrangement between
the Parties and shall not be treated as a partnership. The Parties agree that, to the extent permitted by law, they will report their participation in the Collaboration in accordance with the foregoing. 

 

	10.	REPRESENTATIONS AND WARRANTIES 

 10.1 By Each Party. PTI and King each represents and warrants to the other as of the Effective Date as follows: 

  
 24 









 (a) Organization. It is a corporation duly organized, validly existing and is in
good standing under the laws of the jurisdiction of its organization, is qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the performance of its obligations hereunder requires such
qualification, and, except as would not have a material adverse effect on the ability of the Party to perform its obligations hereunder, has all requisite power and authority, corporate or otherwise, to conduct its business as now being conducted,
to own, lease, and operate its properties and to execute, deliver, and perform this Agreement. 
 (b) Authorization and
Right to Grant Licenses. The execution, delivery, and performance by it of this Agreement have been duly authorized by all necessary corporate action and do not and will not (i) require any consent or approval of its stockholders or
(ii) violate any provision of any agreement, law, rule, regulation, order, writ, judgment, injunction, decree, determination, or award presently in effect having applicability to it or any provision of its charter documents. Each Party has the
right, power, and authority to grant licenses granted by it hereunder. 
 (c) Binding Agreement. This Agreement is a
legal, valid, and binding obligation of it, enforceable against it in accordance with its terms and conditions, except as enforceability may be limited by bankruptcy, insolvency, or other laws affecting the enforcement of creditors’ rights
generally, and except that the availability of the remedy of specific performance or other equitable relief is subject to the discretion of the court before which any proceeding therefor may be brought. 

(d) No Inconsistent Obligation. It is not under any obligation to any person or entity, contractual or otherwise, that is
conflicting or inconsistent in any respect with the terms of this Agreement, and it has all power and authority under all instruments or agreements to which it is a Party to enter into this Agreement and to perform its obligations hereunder.

 (e) Absence of Actions. To its Knowledge, it is not a party to or object of any litigation, suit, legal claim,
action, proceeding, judgment, settlement, or investigation (an “Action”) pending or threatened against it, or any of its Affiliates, or any of its properties or assets, before any governmental authority or Regulatory Authority that
might reasonably be expected to have a material adverse effect on its ability to diligently and completely fulfill its obligations hereunder.A material breach of or inaccuracy in this Section 10.1(e) with respect to a Party shall constitute a
material breach of this Agreement by such Party pursuant to Section 9.2.3. 
 (f) Applicable Law. It has complied
with and shall continue to comply with and shall perform all its duties and obligations hereunder in accordance with all Applicable Law. 
 (g) Debarment. As of the date hereof, neither it nor any of its respective employees or agents, in their capacity as such, have been disqualified or debarred by the FDA, pursuant to 21 U.S.C.
§ 335(a) or (b), or been charged with or convicted under any Applicable Law of the United States for conduct relating to the development or approval, or otherwise relating to the regulation of any Product under the Generic Drug Enforcement Act
of 1992, or any other relevant law, rule, or regulation or been disbarred, disqualified, or convicted under or for any equivalent or similar applicable foreign law, rule, or regulation. 

10.2 By PTI. PTI further represents and warrants to King as of the Effective Date as follows: 

(a) Clinical Trials. All pre-clinical and clinical work, studies, and trials conducted, supervised, or monitored by PTI with
respect to any Designated Product and that are intended to be used to support Regulatory Approval, have, to the Knowledge of PTI, been conducted and performed in substantial compliance with Applicable Laws, including Good Laboratory Practice, Good
Clinical Practice, and Good Manufacturing Practice requirements and ICH Guidelines. PTI has, or, as applicable, any Third Parties with whom PTI has contracted to perform any clinical trials or modifications thereto with respect to any Designated
Product has, to the Knowledge of PTI, obtained and maintained any necessary IRB approvals of clinical trials or modifications thereto sponsored by PTI. To the Knowledge of PTI, in no clinical trial sponsored, conducted, supervised, or monitored by
PTI with respect to any Designated Product has any IRB, ethics committee, or European competent authority approval ever been suspended, terminated, put on clinical hold, or voluntarily withdrawn. 

  
 25 









 (b) Disclosure. To PTI’s Knowledge, no employees or agents of PTI have made an
untrue statement of material fact on behalf of PTI to any Regulatory Authority with respect to any product in the Field or failed to disclose a material fact required to be disclosed to any Regulatory Authority with respect to any product in the
Field that at the time such disclosure was made, could reasonably be expected to (i) provide a basis for the FDA or any other Regulatory Authority to invoke its policy respecting Fraud, Untrue Statements of Material Facts, Bribery, and Illegal
Gratuities, set forth in 56 Fed. Reg. 46191 (September 10, 1991) or any similar policy or (ii) otherwise materially adversely affect the prospect of, or materially delay the obtaining of, Regulatory Approval for such product. 

(c) Intellectual Property. To the actual knowledge of Remi Barbier, Nadav Friedmann, Michael Zamloot, Grant Schoenhard, and Peter
Roddy, the manufacture, use, offer for sale, sale, or importation of the Designated Products (provided that King acknowledges PTI has not conducted any patent search with regard to hydrocodone), in each case as such Designated Product is
specifically formulated, will not infringe or misappropriate the intellectual property rights of any Third Party as of the Effective Date, specifically excluding from such representation and warranty the patents that have been identified by patent
number to King prior to the Effective Date (it being acknowledged by King that PTI has not conducted, among other things, a comprehensive analysis of the other family members of the patent families to which such identified patents belong); provided,
however, that with regard to infringement or misappropriation of the intellectual property rights of a Third Party arising from the utilization of the Saber Technology with regard to any such Designated Product (the “Saber
Infringement”), King acknowledges and agrees that the foregoing representation by PTI with respect to the Saber Infringement is based solely on the representation and warranty received by PTI from Durect with regard to the infringement of
Third Party intellectual property rights pursuant to the DLA, and PTI shall have no liability to King with regard to any Saber Infringement beyond the amount of damages or any other remedy that PTI shall receive from Durect as a result of such
breach. 
 (d) No Omissions. No representation or warranty of PTI contained in this Agreement or the License Agreement,
and no written information previously provided by PTI to King in connection with the transactions contemplated hereby, including any representation, warranty, or information relating to any pre-clinical, clinical, manufacturing, or regulatory issues
concerning any Designated Product, contains any untrue statement of a Material Fact or omits to state a Material Fact actually known to PTI and which would be necessary in order to make the statements contained herein or therein not misleading in
light of the circumstances under which they were made. For purposes of this representation and warranty, King shall be deemed to be on notice and to have received disclosures of the following information: (i) with respect to PTI, information
publicly available through PTI’s filings with the Securities and Exchange Commission and the publications listed on Schedule 10.2(d)(i) attached hereto, and, (ii) with respect to Durect, information publicly available through Durect’s
filings with the Securities and Exchange Commission and the publications listed on Schedule 10.2(d)(ii) attached hereto as well as any peer-reviewed publications in English generally available to the public regarding the subject matter of this
Agreement (including Remoxy and the SABER Technology) and written by the individuals set forth on Schedule 10.2(d)(ii). As used in this Section 10.2(d), a “Material Fact” means a fact that would have a materially adverse effect
on the commercial prospects for products in the Field in the Territory taken as a whole. 
  

	11.	INDEMNIFICATION 


11.1 Indemnification of King by PTI. PTI shall indemnify, defend, and hold harmless King, its Affiliates, and their
respective directors, officers, employees, and agents (the “King Indemnitees”), against any liability, damage, loss, or expense (including reasonable attorneys’ fees and expenses of litigation) (collectively,
“Losses”) incurred by or imposed upon the King Indemnitees, or any one of them, as a result of claims, causes of action, suits, actions, demands, or judgments made against such King Indemnitees by Third Parties, including claims for
personal injury and claims of suppliers and PTI employees (except in cases where such claims, suits, actions, demands, or judgments result from a material breach by King of its representations or warranties under this Agreement, gross negligence, or
willful misconduct on the part of King), in each case to the extent arising out of (a) the breach of any representation or warranty of PTI under Article 10hereof, (b) the gross negligence or willful misconduct of PTI, its Affiliates, or
their respective employees or agents in the performance of any obligation under this Agreement, and (c) any government funding received by PTI prior to the Effective Date in connection with the research or development of any Products or any
subject matter disclosed in any PTI Patent Rights, including 

  
 26 









 
pursuant to any grants from the National Institutes of Health, and the failure of PTI to comply in all material respects with the terms and conditions of such funding agreements and grants, and
with all Applicable Laws with respect thereto, including to obtain any necessary permits or waivers thereunder. For purposes of clarity, it is understood and agreed that, except as provided in this Section 11.1 or in Section 9.1 of the
License Agreement, PTI provides no indemnification to King with respect to product liabilities claims relating to Products. 

11.2 Indemnification of PTI by King. King shall indemnify, defend, and hold harmless PTI, its Affiliates, and their
respective directors, officers, employees, and agents (the “PTI Indemnitees”), against any Losses incurred by or imposed upon the PTI Indemnitees, or any one of them, as a result of claims, causes of action, suits, actions, demands,
or judgments made against such PTI Indemnitees by Third Parties, including personal injury and claims of suppliers and King employees (except in cases where such claims, suits, actions, demands, or judgments result from a material breach by PTI of
its representations or warranties under this Agreement, gross negligence, or willful misconduct on the part of PTI), in each case to the extent arising out of (a) the breach of any representation or warranty of King under Article 10hereof and
(b) the gross negligence or willful misconduct of King, its Affiliates, or their respective employees or agents in the performance of any obligation under this Agreement. For purposes of clarity, it is understood and agreed that, except as
provided in this Section 11.2 or in Section 9.2 of the License Agreement, King provides no indemnification to PTI with respect to product liabilities claims relating to Products. 

11.3 Conditions to Indemnification. A Party seeking indemnification under this Article 11 (the “Indemnified
Party”) shall give prompt notice of the claim to the other Party (the “Indemnifying Party”) and, provided that the Indemnifying Party is not contesting the indemnity obligation, shall permit the Indemnifying Party to
control any litigation relating to such claim and disposition of any such claim. The Indemnifying Party shall act reasonably and in good faith with respect to all matters relating to the settlement or disposition of any claim as the settlementor
disposition relates to Parties being indemnified under this Article 11. The Indemnifying Party shall not settle or otherwise resolve any claim without prior notice to the Indemnified Party and the consent of the Indemnified Party (which consent
shall not be unreasonably withheld, conditioned, or delayed) if such settlement involves anything other than the payment of money by the Indemnifying Party. The Indemnified Party shall reasonably cooperate with the Indemnifying Party in its defense
of any claim for which indemnification is sought under this Article 11and shall have the right to be present in person or through counsel at all legal proceedings giving rise to the right of indemnification. For purposes of clarity, it is understood
that in the event that a claim is eligible for indemnification under both this Article 11 and under Article 9 of the License Agreement, the Indemnified Party shall be entitled to seek indemnification for such claim under either this
Agreement or the License Agreement, but not both. 
 11.4 Insurance. In addition to the insurance coverages
required by Section 5.1 hereof, each Party shall obtain other insurance coverage from first class insurers in types and amounts commensurate with industry standards for such Party’s activities hereunder. 

11.5 Warranty Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT OR THE LICENSE AGREEMENT, NEITHER PARTY
MAKES ANY WARRANTY WITH RESPECT TO ANY TECHNOLOGY, GOODS, SERVICES, RIGHTS, OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND HEREBY DISCLAIMS WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT WITH RESPECT TO ANY AND
ALL OF THE FOREGOING. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, NEITHER PARTY MAKES ANY GUARANTEES TO THE OTHER CONCERNING THE SUCCESS OR POTENTIAL SUCCESS OF THE ACTIVITIES CONTEMPLATED UNDER THIS AGREEMENT. 

11.6 Limited Liability. EXCEPT WITH RESPECT TO A BREACH OF THE OBLIGATIONS IN ARTICLE 8 OR WITH RESPECT TO AMOUNTS PAID TO
THIRD PARTIES UNDER THE INDEMNIFICATION OBLIGATIONS OF THIS ARTICLE 11, NEITHER PTI NOR KING WILL BE LIABLE WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY, OR OTHER LEGAL OR EQUITABLE THEORY FOR
(I) ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES OR (II) COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY, OR SERVICES. 

  
 27 










	12.	REMEDIES 

 Subject
to the terms of this Agreement, the Parties are not excluded from exercising or seeking any and all rights and remedies available, in law or in equity, under Applicable Law. 

 

	13.	MISCELLANEOUS 


13.1 Notices. All notices or other communications that shall or may be given pursuant to this Agreement shall be in writing
and shall be deemed to be effective (a) simultaneously with the transmission or delivery thereof, if sent by facsimile transmission (followed by hard copy by mail), (b) when delivered, if sent by United States registered or certified mail,
return receipt requested, or (c) on the next business day, if sent by overnight courier, in each case to the Parties at the following addresses (or at such other addresses as shall be specified by like notice) with postage or delivery charges
prepaid: 
  

			
	 If to King:
	  	If to PTI:
		
	 King Pharmaceuticals, Inc.

501 Fifth Street
 Bristol, Tennessee 37620
 Tel.:
(423) 989-8000
 Fax: (423) 990-2566

Attention: General Counsel
	  	 Pain Therapeutics, Inc.
 416
Browning Way
 South San Francisco, California 94080
 Tel.: (650) 825-3342
 Fax: (650) 624-8222
 Attention: President & CEO

		
	 With a copy to:
	  	With a copy to:
		
	 King Pharmaceuticals, Inc.

501 Fifth Street
 Bristol, Tennessee 37620
 Tel.:
(423) 989-8000
 Fax: (423) 274-2602

Attention: Business Development
	  	 Wilson Sonsini Goodrich &Rosati
 650 Page Mill Road
 Palo Alto, California 94304-1050

Tel.: (650) 493-9300
 Fax: (650)
493-6811
 Attention: Michael O’Donnell


 13.2 Governing Law. This Agreement shall be governed by and construed in accordance with
the laws of the State of New York, without regard to the application of principles of conflicts of law. 
 13.3 Binding
Effect. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors, and permitted assigns. 

  
 28 









 13.4 Counterparts. This Agreement may be executed simultaneously in two or
more counterparts, each of which shall be deemed an original. 
 13.5 Amendment; Waiver. This Agreement may be
amended, modified, superseded, or canceled, and any of the terms may be waived, only by a written instrument executed by each Party or, in the case of waiver, by the Party or Parties waiving compliance. The delay or failure of any Party at any time
or times to require performance of any provisions shall in no manner affect the rights at a later time to enforce the same. No waiver by any Party of any condition or of the breach of any term contained in this Agreement, whether by conduct, or
otherwise, in any one or more instances, shall be deemed to be, or considered as, a further or continuing waiver of any such condition or of the breach of such term or any other term of this Agreement. 

13.6 No Third Party Beneficiaries. No Third Party, including any employee of any Party to this Agreement, shall have or
acquire any rights by reason of this Agreement. 
 13.7 Purposes and Scope. The Parties hereto understand and
agree that this Development Program is limited solely to the Field in the Territory, and to the activities, rights, and obligations as set forth in this Agreement. Nothing in this Agreement shall be construed (a) to create or imply a general
partnership between the Parties, (b) to make either Party the agent of the other for any purpose, (c) to alter, amend, supersede, or vitiate any other arrangements between the Parties with respect to any subject matters not covered
hereunder, (d) to give either Party the right to bind the other, (e) to create any duties or obligations between the Parties except as expressly set forth herein, or (f) to grant any direct or implied licenses or any other right other
than as expressly set forth herein. 
 13.8 Performance by Affiliates. Each Party shall have the right to direct
its wholly-owned Affiliates to act in satisfaction of such Party’s or Affiliate’s obligations hereunder or make an assignment to an Affiliate in accordance with Section 13.9; provided that such Party shall remain liable and fully
responsible for the performance of such Affiliate hereunder. 
 13.9 Assignment and Successors. Neither this
Agreement nor any obligation of a Party hereunder may be assigned by either Party without the consent of the other, except that, subject to Section 9.4.1, each Party may assign this Agreement and the rights, obligations, and interests of such
Party, in whole or in part, to any of its Affiliates (subject to Section 13.8) or to any Third Party that succeeds to all or substantially all of a Party’s business or assets relating to this Agreement and the License Agreement, whether by
sale, merger, operation of law, or otherwise; provided that such assignee or transferee promptly agrees in writing to be bound by the terms and conditions of this Agreement. Any attempted assignment in violation of this Section 13.9 shall be
null, void, and of no effect. This Agreement shall be binding upon and inure to the benefit of all permitted successors-in-interest and assigns. 
 13.10 Force Majeure. In the event of the occurrence of a Force Majeure Event, the Parties shall not be deemed in breach of their obligations to the extent of the Force Majeure Event. The
Party affected thereby shall use reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder. 
 13.11 Interpretation. 
 (a) The Parties hereto acknowledge and
agree that: (i) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (ii) the rule of construction to the effect that any ambiguities are resolved against the
drafting Party shall not be employed in the interpretation of this Agreement;and (iii) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which
Party was generally responsible for the preparation of this Agreement. 
 (b) The headings contained in this Agreement are for
reference purposes only and will not affect in any way the meaning or interpretation of this Agreement. Whenever the words “include,” “includes,” or “including” are used in this Agreement, they will be deemed to be
followed by the words “without limitation.” Unless the context otherwise requires, (i) “or” is disjunctive but not necessarily exclusive, (ii) words in the singular include the plural and vice versa, and (iii) the
use in this Agreement of a pronoun in reference to a Party hereto includes the masculine, feminine, or neuter, as the context may require. The Annex, Schedules, and Exhibits hereto will be deemed part of this Agreement and included in any reference
to this Agreement. 

  
 29 









 13.12 Integration; Severability. This Agreement and the License Agreement,
when executed, are the sole agreements with respect to the subject matter hereof and supersede all other agreements and understandings between the Parties with respect to same. If any provision of this Agreement (including the temporal and
substantive scope of the restrictions set forth in Article 7) is or becomes invalid or is ruled invalid by any court of competent jurisdiction or is deemed unenforceable, such provision or portion thereof will be modified or deleted in such a manner
so as to make this Agreement, as modified, legal and enforceable to the fullest extent permitted under Applicable Law, and it is the intention of the Parties that the remainder of the Agreement shall not be affected. 

13.13 Further Assurances. Each of PTI and King agrees to duly execute and deliver, or cause to be duly executed and
delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such additional assignments, agreements, documents, and instruments, that may be necessary or as the other Party hereto may at any
time and from time to time reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes of, or to better assure and confirm unto such other Party its rights and remedies under, this Agreement.

 [Remainder of page intentionally left blank] 

  
 30 









 IN WITNESS WHEREOF, the Parties have caused this Collaboration Agreement to be
executed by their duly authorized representatives as of the Effective Date. 
  

			
	PAIN THERAPEUTICS, INC.
		
	 By:
	 	 /s/ Remi Barbier

		 	Name: Remi Barbier
		 	Title: President & CEO


  

			
	KING PHARMACEUTICALS, INC.
		
	 By:
	 	 /s/ Brian A. Markison

		 	Name: Brian A. Markison
		 	Title: President and Chief Executive Officer



  








 ANNEX A 
 DEFINITIONS TO COLLABORATION AGREEMENT 
 1
“AAA” has the meaning set forth in Section 2.3.3 of this Agreement. 
 2
“Action” has the meaning set forth in Section 10.1(e) of this Agreement. 
 3
“Affiliate” means any corporation, firm, partnership, or other entity that directly or indirectly controls or is controlled by or is under common control with a Party to this Agreement. For purposes of this definition,
“control” means ownership, directly or through one or more Affiliates, of (a) 50% or more of the shares or voting rights in the case of a corporation or limited company, (b) 50% or more of the shares of stock entitled to vote for
the election of directors, in the case of a corporation, (c) 50% or more of the equity or controlling interests in the case of any other type of legal entity (including joint ventures) or status as a general partner in any partnership, or
(d) any other arrangement whereby a Party controls or has the right to control the Board of Directors or equivalent governing body of an entity. 
 4 “Agreement” means this Collaboration Agreement, including all attached exhibits, schedules and annexes, as well as all amendments, supplements, and restatements thereof.

 5 “API” means, with respect to a Product, the active pharmaceutical ingredient used in the Product.

 6 “Applicable Law” means applicable U.S. and foreign laws, rules, regulations, guidelines, and
standards, including those of the FDA and comparable foreign Regulatory Authorities. 
 7 “Bankruptcy
Code” means the U.S. Bankruptcy Code, 11 U.S.C. §§ 101 et seq. 
 8 “Calendar
Quarter” means, with respect to the first such Calendar Quarter, the period beginning on the Closing Date and ending on the last day of the calendar quarter within which the Closing Date falls and, thereafter, each successive period of
three consecutive calendar months ending on March 31, June 30, September 30, or December 31. In the event that the termination of this Agreement does not fall on the last day of a Calendar Quarter, the “Final
Calendar Quarter” shall mean the period from the last day of the most recent Calendar Quarter through the applicable date of termination of this Agreement. 
 9 “Calendar Year” means each successive twelve (12)-month period commencing on January 1 and ending on December 31; provided that the first such Calendar Year shall begin
on the Closing Date and end on December 31, 2005. In the event that the termination of this Agreement does not fall on the last day of a Calendar Year, the “Final Calendar Year” shall mean the period from the last day of
the most recent Calendar Year through the applicable date of termination of this Agreement. 
 10
“Claims” has the meaning set forth in Section 5.1 of this Agreement. 
 11
“Closing” shall mean, subject to the satisfaction or waiver of the conditions set forth in Section 6.1.3 of this Agreement, the closing of the transactions contemplated by this Agreement. 

12 “Closing Date” shall mean the earlier of: (a) the third day, unless the first day falls on a weekend or
holiday, in which case it shall be the next business day, after the expiration or termination of all applicable waiting periods under the HSR Act and the satisfaction of all the other conditions set forth in Section 6.1.3 of this Agreement or
(b) the third day, unless the first day falls on a weekend or holiday, in which case it shall be the next business day, after the joint determination (by certification from each Party to the other) that notification under the HSR Act is not
required and the satisfaction of all the other conditions set forth in Section 6.1.3 of this Agreement. 
 13
“CMC” means, with respect to a Product, the chemistry, manufacturing, and controls information that would typically be, or is, included in an IND or NDA for such Product. 







 14 “Co-Chairman” has the meaning set forth in Section 2.1 of
this Agreement. 
 15 “Collaboration” means the association of PTI and King established pursuant to this
Agreement for the purpose of conducting the Development of Products so as to accomplish the Development objectives of the Development Program. 
 16 “Collaboration Costs” means the sum of each of the following costs incurred by or on behalf of a Party in fulfilling its responsibilities under the Development Program in
accordance with the Program Plans for such Product, which costs must be documented and supported, calculated in accordance with Sections 3.3.2 and 3.7 of this Agreement, and included in the budget of a Program Plan or otherwise approved by King:

 16.1 all out-of-pocket costs, including amounts paid to Durect for materials and services PTI is obligated to obtain from
Durect under the DLA and any capital expenses for equipment purchased for purposes of fulfilling PTI’s obligations under the Agreement (provided that the cumulative costs for such capital equipment shall not exceed two million U.S. dollars
($2,000,000) and provided further that King shall have title to any such capital equipment which it funds); 
 16.2 all internal
labor costs incurred by a Party in connection with its research employees dedicated to providing services relating to a Product, such costs to be calculated by multiplying the Hourly FTE Rate by the total number of hours expended by such
Party’s personnel in performance of such services; provided that no time of PTI’s Chief Executive Officer, Chief Financial Officer, or any administrative personnel of PTI will be billed to the Collaboration; and 

16.3 any other costs expressly provided for in this Agreement or a Project Plan. 

Except to the extent this Agreement expressly provides for payments that do not require such approval, and except to the extent King has approved any
payment hereunder, neither Party shall (i) be obligated to incur any costs or expend any funds that have not been approved by such Party or (ii) have the authority to cause the other Party to incur any costs or expend any funds that have
not been approved by such other Party. Notwithstanding anything to the contrary contained herein, Collaboration Costs shall not include (A) except to the extent included in the FTE Rate, indirect costs, overhead, general, and administrative
costs and other similar costs of a Party, or (B) any costs that relate to the business of a Party as a whole without specifically relating to a Product. In calculating the Collaboration Costs, the following principles shall apply:
(1) there shall be no double counting of any costs or expenses or of any revenues; (2) when allocating costs and expenses under this Agreement, each Party shall utilize the same policies and principles as it utilizes consistently within
its group and business units when making internal cost allocations; and (3) all costs and expenses shall be determined, and all calculations shall be made, in accordance with GAAP. 

17 “Completion of Phase II” means completion of the final statistical results of clinical trials that
collectively evaluate the safety and efficacy of a Product’s specific dosage strength in an indication the Product is intended to treat, which data enables the Parties to proceed with pivotal registration Phase III studies, without any
objection from the FDA, as documented by FDA contact reports. For the avoidance of doubt, the “Completion of Phase II” for each Product in the Collaboration shall be independent events. 

18 “Confidential Information” means all information, Technology, and Proprietary Materials that are disclosed to
a Party (the “Receiving Party”) by or on behalf of the other Party (the “Disclosing Party”) hereunder or under the License Agreement or disclosed to any of the Receiving Party’s employees, Consultants,
Affiliates, or Sublicensees, except to the extent that any such information (a) as of the date of disclosure is known to the Receiving Party or its Affiliates, as demonstrated by credible written documentation; (b) as of the date of
disclosure is in, or subsequently enters, the public domain, through no fault or omission of the Receiving Party; (c) is obtained from a Third Party having a lawful right to make such disclosure free from any obligation of confidentiality to
the Disclosing Party; or (d) is independently developed by or for the Receiving Party without reference to or reliance upon any Confidential Information of the Disclosing Party as demonstrated by credible written documentation. It is further
agreed that PTI Technology shall be deemed the Confidential Information of PTI, King Technology shall be deemed the Confidential Information of King, and Joint Technology shall be deemed the Confidential Information of both Parties. During the Term
hereof, neither Party shall discloseany of its own Confidential Information in such 

  
 - 2 -









 
a manner that would reasonably be expected to adversely impact any intellectual property rights or commercial interests of the Development Program or the Products, unless such disclosure is
subject to confidentiality obligations as strict as those contained in this Agreement or the License Agreement. 
 19
“Consultant” means a Third Party who has entered into or hereafter enters into a written agreement with PTI or King or both to provide consulting services that are material or are reasonably likely, in the judgment of the
JOC, to become material to the Development Program, which written agreement shall (a) include an assignment of all right, title, and interest in and to all work product and all inventions arising from the performance of such agreement, and all
intellectual property rights attaching thereto, to PTI or King, as applicable, and (b) bind the relevant Third Party by obligations of confidentiality and non-use with respect to all such work product, inventions, Confidential Information, and
intellectual property rights that are at least as stringent as those set forth herein. 
 20
“Consultation” means providing a Party with an opportunity to review and comment on the development of strategies and the implementation of Program Plans, permitting a Party to participate in, where practical, either by
telephone or in person, and to examine formal minutes of, all meetings and telephone calls with respect to a matter under consideration, keeping a Party informed regarding the progress of all matters, and giving due consideration to the input and
comments of a Party with respect to the matters under consideration. 
 21 “Control” or
“Controlled” means, (a) with respect to Technology (other than Proprietary Materials) or Patent Rights, the possession by a Party of the ability to grant a license or sublicense of such Technology or Patent Rights as
provided herein without the payment of additional consideration (other than any additional consideration to be paid pursuant to the DLA) and without violating the terms of any agreement or arrangement between such Party and any Third Party and,
(b) with respect to Proprietary Materials, the possession by a Party of the ability to supply such Proprietary Materials to the other Party as provided herein without the payment of additional consideration and without violating the terms of
any agreement or arrangement between such Party and any Third Party. 
 22 “Crain/Shen Drug” means any
dosage form that is covered by any patent or patent application set forth on Schedule 22 hereto (the “Existing Patents”), as well as any continuations, divisionals, continuations-in-part (to the extent any claims thereof are entitled to
claim priority to the filing date of any of the Existing Patents), patents of addition, and substitutions of the Existing Patents, together with all registrations, reissues, reexaminations or extensions of any kind with respect to any of the
foregoing patents, in each case to the extent same are owned or controlled by PTI. In the event PTI reasonably believes that any claims of a continuation-in-part application of any of the Existing Patents, which claims are not entitled to claim
priority to the filings date of any of the Existing Patents, cover only an incremental improvement to the subject matter described and claimed in the Existing Patents, PTI shall have the right to request that King permit such additional claims to be
included within the definition of Crain/Shen Drugs, and King shall consider such request in good faith. Notwithstanding the foregoing, with respect to United States Application Serial Nos. 10/119,615 and 10/742,672, and any applications or patents
that claim priority to either of same, to the extent that any claims cover a dosage form of an opioid agonist alone or a method or process of using or making such a dosage form, such claims shall not be within the definition of Crain/Shen Drug, but
shall be considered PTI Technology and PTI Patent Rights (and such applications and issued patents will be included on the schedule of PTI Patent Rights solely to such extent). 

23 “Crain/Shen SABER Drug” means any dosage form of a Crain/Shen Drug that (a) contains oxycodone,
hydromorphone, oxymorphone or hydrocodone as the only opioid agonist API and (b) is covered by the rights granted to PTI under the DLA. 
 24 “CTM” or “Clinical Trial Materials” means any Product manufactured, packaged, and labeled as required by Applicable Law to be used as an investigational
drug or placebo for use in the conduct of clinical trials in humans. 
 25 “Debtor Party” has the
meaning set forth in Section 9.4.1(a) of this Agreement. 
 26 “Default” means (a) a material
breach, default, or violation, (b) for purposes of Section 5.3 of this Agreement only, the occurrence of an event that with or without the passage of time or the giving of notice, or both,


  
 - 3 -









 
would constitute a material breach, default, or violation or cause any material mortgages, liens, security interests, charges, covenants, options, claims, restrictions, and encumbrances of any
kind to arise, or (c) for purposes of Section 3.8 of this Agreement only, the occurrence of an event that with or without the passage of time or the giving of notice, or both, would give rise to a right of termination, renegotiation, or
acceleration or a material right to receive damages or a payment of material monies or penalties of or under such contract by a party other than a Party. 
 27 “Defaulting Party” has the meaning set forth in Section 3.8 of this Agreement. 
 28 “Designated Product” means a Product being developed by PTI as of the Effective Date (i.e., the first three (3) products specified in Section 3.1.1 of this
Agreement, namely one (1) Product having oxycodone as the opioid API (Remoxy), one (1) Product having hydromorphone as the opioid API, and one (1) Product having hydrocodone as the opioid API); and “Designated
Products” means, collectively, all of the foregoing Products. 
 29 “Development” or
“Develop” means, with respect to a Product, all research, pre-clinical, pharmaceutical, clinical, and regulatory activities and all other activities undertaken in order to obtain Regulatory Approval of such Product in
accordance with this Agreement prior to Regulatory Approval of such Product. These activities shall include, among other things: test method development, CMC methods and reports (including formulation, process development, development-stage
manufacturing, manufacturing scale-up, technical transfer, quality assurance, and quality control), pre-clinical pharmacology and toxicology studies and associated reports, planning and conduct of clinical studies, protocols, clinical study reports,
statistical analysis plans, and clinical quality assurance prior to obtaining Regulatory Approvals, obtaining Regulatory Approvals, and regulatory affairs related to the foregoing. 

30 “Development Plans” means the written plans (which shall include detailed strategy, budget, and proposed
timelines) describing the pre-clinical and clinical Development activities and the regulatory activities, including a general overview of the expected schedule of meetings, discussions, and correspondence with Regulatory Authorities to be carried
out for each Product during each Calendar Year pursuant to this Agreement, which plans shall include the expected Regulatory Filings to be completed and maintained by the Collaboration for each Product. The Development Plans will be amended from
time to time to include statistical analysis plans, protocols, case report forms, clinical study reports, audit reports, and similar matters, as such matters are developed during the Collaboration. Without limiting the foregoing, such plans shall
include, at a minimum, the activities required to remain in compliance with the terms and obligations applicable to PTI under the DLA. Each Development Plan will be set forth in a written document prepared by the Parties pursuant to Section 3.4
of this Agreement, and a separate Development Plan will be generated and approved with respect to each Product. 
 31
“Development Program” means, collectively, (a) the collaborative development program in the Field conducted by PTI and King and (b) the marketing program in the Field conducted by King, in each case, commencing on
the date hereof and conducted pursuant to this Agreement and the Program Plans. 
 32 “Discretionary
Funding” has the meaning set forth in Section 3.7.3 of this Agreement. 
 33 “Durect License
Agreement” or “DLA” means the Development and License Agreement, dated as of December 19, 2002, by and among PTI, DURECT Corporation (“Durect”), and Southern BioSystems, Inc., a copy
of which has been provided to King, as it may be amended from time to time hereafter in accordance with Section 2.4 of the License Agreement. 
 34 “Effective Date” has the meaning set forth in the first paragraph of this Agreement. 
 35 “Existing Management Team” means not less than fifty percent (50%) of the individuals who, as of the date that is one year prior to the commencement of any case by or
against PTI under the Bankruptcy Code, are designated as “Officers” of PTI under Rule 16a-1(f) promulgated pursuant to the Securities Exchange Act of 1934, as amended. 

36 “FDA” means the United States Food and Drug Administration or any successor agency. 

  
 - 4 -









 37 “Field” means pharmaceutical formulations for use in humans that
contain no more than one opioid API formulated using the SABER Technology, in accordance with the DLA. 
 38 “First
Commercial Sale” means, with respect to any product, the first arm’s-length sale by King, its Affiliates, or Sublicensees to a Third Party for end-use or consumption, including any sale to a wholesaler or distributor, of such
product in a country after the applicable Regulatory Authority has granted Regulatory Approval. For purposes of this definition, any sale to an Affiliate or Sublicensee will not constitute a First Commercial Sale. 

39 “Force Majeure Event” means an event beyond the reasonable control of a Party that prevents the performance,
in whole or in part, by the Party of any of its obligations hereunder, including by reason of any act of God, flood or other inclement weather patterns, fire, explosion, earthquake, or war, terrorist act, revolution, civil commotion, acts of public
enemies, blockage or embargo, or the like, or any injunction, law, order, ordinance, or requirement of any government or of any subdivision, authority, or representative of any such government, if, and only if, the Party affected shall have used
commercially reasonable efforts to avoid the effects of such occurrence and to remedy it promptly if it has occurred. 
 40
“FTE Rate” means a rate of two hundred fifty thousand U.S. dollars ($250,000) per 1,635 hours of work performed by personnel during Calendar Years 2005 and 2006, said rate to be increased as of January 1, 2007, and
annually thereafter to reflect actual increases in the applicable Party’s expenses. 
 41 “GAAP”
means United States generally accepted accounting principles of the Party performing the applicable work, consistently applied. 

42 “Good Clinical Practices” means the international ethical and scientific quality standards for designing,
conducting, recording, and reporting trials that involve the participation of human subjects. In the U.S. Territory, Good Clinical Practices are established through FDA guidances (including ICH E6). 

43 “Good Laboratory Practices” means the minimum standards for conducting non-clinical laboratory studies that
support or are intended to support applications for research or marketing permits for products regulated by the FDA or equivalent foreign Regulatory Authority, including food and color additives, animal food additives, human and animal drugs,
medical devices for human use, biological products, and electronic products. In the U.S. Territory, Good Laboratory Practices are established through FDA regulations (including 21 CFR Part 58), FDA guidances, FDA current review and inspection
standards, and current industry standards. 
 44 “Good Manufacturing Practices” means the minimum
standards for methods to be used in, and the facilities or controls to be used for, the manufacture, processing, packing, or holding of a drug to assure that such drug meets the requirements of the Federal Food, Drug and Cosmetic Act of 1938, or its
foreign equivalent, as amended, as to safety, and has the identity and strength and meets the quality and purity characteristics that it purports or is represented to possess. In the U.S. Territory, Good Manufacturing Practices are established
through FDA regulations (including 21 CFR Parts 210-211), FDA guidances, FDA current review and inspection standards, and current industry standards. 
 45 “Hourly FTE Rate” means the hourly rate obtained by dividing the FTE Rate by 1,635 hours. 
 46 “HSR Act” means the Hart-Scott-Rodino Act of 1976, as amended. 
 47 “IND” means (a) an Investigational New Drug Application (as defined in 21 CFR § 312.3) that is required to be filed with the FDA before beginning clinical testing
of a Product in human subjects, or any successor application or procedure, or (b) any counterpart of a U.S. Investigational New Drug Application that is required in any other country or region in the Territory before beginning clinical testing
of a Product in human subjects in such country or region. 
 48 “Indemnified Party” has the meaning set
forth in Section 11.3 of this Agreement. 
 49 “Indemnifying Party” has the meaning set forth in
Section 11.3 of this Agreement. 

  
 - 5 -









 50 “Invent” or “Invented” means
(a) with respect to patentable Technology, to invent or discover, as such terms are used in 35 U.S.C. § 101 and (b) with respect to non-patentable Technology, to discover, make or otherwise develop. 

51 “IRB” means an Institutional Review Board or any constituted group that has been formally designated by a
clinical site to review and monitor biomedical research involving human subjects. 
 52 “Joint Oversight
Committee” or “JOC” means the committee of PTI and King representatives established pursuant to Section 2.1 of this Agreementto administer the affairs of the Development Program. 

53 “Joint Patent Rights” means Patent Rights claiming Joint Technology, as set forth on Schedule 53 hereto, which
may be amended from time to time as necessary to accurately reflect the foregoing. 
 54 “Joint
Technology” means any Technology jointly Invented by employees of King and PTI, or Consultants to King and PTI, during and in the conduct of the Development Program. 

55 “King” has the meaning set forth in the first paragraph of this Agreement. 

56 “King Background Technology” means any Technology that is useful in the Field or that is actually used in the
Development, making or Marketing of Products and that is Controlled by King on the Closing Date. 
 57 “King
Indemnitees” has the meaning set forth in Section 11.1 of this Agreement. 
 58 “King Patent
Rights” means all Patent Rights that are Controlled by King and that claim King Technology, as set forth on Schedule 58 hereto, which may be amended from time to time as necessary to accurately reflect the foregoing. 

59 “King Program Technology” means any Technology that is (a) Invented by employees of, or Consultants to,
King, alone or jointly with Third Parties (other than Consultants of PTI), in the conduct of the Development Program or (b) useful in the Field or that is actually used in the Development, manufacturing or Marketing of Products and that are
acquired by King after the Closing Date pursuant to a Third Party Agreement. 
 60 “King Technology”
means, collectively, King Background Technology and King Program Technology. 
 61 “Knowledge” means the
actual knowledge of a Party having taken reasonable steps to be informed of applicable actions and activities in the normal course of business. 
 62 “License Agreement” means that certain License Agreement to be executed by the Parties in the form attached hereto as Exhibit A. 

63 “Losses” has the meaning set forth in Section 11.1 of this Agreement. 

64 “Major Market Country” means one of Canada, Germany, the United Kingdom, France, Spain, Italy, or Japan; and
“Major Market Countries” means, collectively, all of the foregoing countries. 
 65
“Manufacturing/CMC Plans” means the written CMC and manufacturing plans (which shall include a detailed strategy, budget, and proposed timelines) describing the API, synthesis, choice of manufacturers and Third Party
suppliers, expected manufacturing scale-up, manufacture, formulation, process development, development-stage manufacture, clinical supplies manufacturing, quality assurance/quality control development, stability, filling, packaging and labeling, and
shipping requirements for each Product (in accordance with customary standards for a product of comparable market potential), including all CMC, and the activities to be carried out by each Party during the applicable Calendar Year. Each
Manufacturing/CMC Plan will be set forth in a written document prepared by the Parties pursuant to Section 3.5 of this Agreement, and a separate Manufacturing/CMC Plan will be generated and approved with respect to each Product. 

  
 - 6 -









 66 “Market” or “Marketing” means any and all
activities directed to the marketing, detailing, and promotion of a Product for commercial sale and shall include pre-launch and post-launch marketing, mandated and non-mandated risk-management policies and procedures, market surveillance
activities, promoting, detailing, distributing (including the cost and distribution of Product samples), offering to sell, and selling a Product, importing a Product for sale, and any and all Product Development conducted after obtaining marketing
approval for any Product that is not performed as a condition to the first Regulatory Approval for a Product. If a Phase IV trial is performed as a condition to fulfill an obligation for Regulatory Approval for a Product, such trial shall be
considered a Development activity (but not Product Development). 
 67 “NDA” means a New Drug
Application (or an abbreviated New Drug Application) to market the Product in the Territory or similar application submitted to the FDA, or its foreign equivalent submitted to any Regulatory Authority in the Territory, and all supplements and
amendments thereto. 
 68 “Net Sales” means the gross amount invoiced by King its Affiliates or
Sublicensees, to Third Parties for sale of Products, less, to the extent deducted from such amount or on such invoice consistent with GAAP, the following items: (a) quantity, trade or cash discounts, chargebacks, returns, allowances, rebates
(including any and all federal, state or local government rebates, such as Medicaid rebates) and price adjustments, to the extent actually allowed; (b) sales and other excise taxes and duties or similar governmental charges levied on such sale,
to the extent such items are included in the gross invoice price; (c) amounts actually refunded due to rejected, spoiled, damaged, outdated or returned Product; and (d) freight, shipment and insurance costs actually incurred in
transporting Product to a Third Party purchaser. If any Products are sold to Third Parties in transactions that are not at arm’s length between the buyer and seller, or for consideration other than cash, then the gross amount to be included in
the calculation of Net Sales for such sales shall be the amount that would have been invoiced had the transaction been conducted at arm’s length, which amount shall be determined, whenever possible, by reference to the average selling price of
the relevant Product in arm’s-length transactions in the country of sale at the time of sale. Net Sales shall not include amounts invoiced for the supply, disposal of Product for, or use of Product, in clinical or pre-clinical trials or as free
samples (such samples to be in quantities common in the industry for this sort of Product). 
 69 “Non-Debtor
Party” has the meaning set forth in Section 9.4.1(a) of this Agreement. 
 70 “Non-Defaulting
Party” has the meaning set forth in Section 3.8 of this Agreement. 
 71 “Party” or
“Parties” has the meaning set forth in the first paragraph of this Agreement. 
 72 “Patent
Rights” means the rights and interests in and to issued patents and pending patent applications (which for purposes of this Agreement shall be deemed to include certificates of invention and applications for certificates of invention
and priority rights) in any country, including all provisional applications, substitutions, continuations, continuations-in-part, divisions, and renewals, all letters patent granted thereon, and all reissues, reexaminations and extensions thereof.

 73 “Phase II” means a human clinical trial or trial program in any country that is intended to
evaluate the safety and efficacy of a Product’s dose and dose regimen in a specific indication the Product is intended to treat. 
 74 “Phase II Meeting” means, with respect to a Product, the meeting with the FDA held at the end of Phase II, it being agreed that King shall have the right to participate in the
preparations and planning conducted in anticipation of or in connection with such meeting. 
 75 “Phase
III” means a human clinical trial in any country that would otherwise meet the definition of 21 CFR 312.21(c), or its foreign equivalent. 

  
 - 7 -









 76 “Product” means (a) any dosage form of Remoxy, and
(b) any other product in the Field (i) that incorporates the SABER Technology and is covered by the rights licensed to PTI under the DLA, and (ii) that is Developed or Marketed pursuant to this Agreement. For purposes of clarity,
“Product” includes those products within the Field that the Parties have agreed to Develop and Market as of the Effective Date, as well as any and all other products in the Field that King actually designates to be Developed or Marketed
under this Agreement during the Term thereof. 
 77 “Product Development” means (a) with respect to
the U.S. Territory, the conduct by King and its Affiliates of additional clinical studies of a Product that has previously received Regulatory Approval from the FDA, which additional clinical studies are conducted using CTM that is in the same
formulation and dosage form as the Product for which Regulatory Approval was previously obtained, and (b) with respect to the ROW, the conduct by King, its Affiliates, or its Sublicensees of clinical studies of a Product, which additional
clinical studies are conducted using CTM that is in the same formulation and dosage form as the Product for which Regulatory Approval was previously obtained in the U.S. Territory (or if Regulatory Approval has not yet been obtained in the U.S.
Territory, then using CTM in the same formulation(s) and dosage form(s) then being utilized by PTI under the Development Plan for such Product in the U.S. Territory). For purposes of clarity, Product Development shall include the right (i) to
use the clinical data generated in such clinical studies to seek additional Regulatory Approvals for a Product and engage in associated regulatory activities and (ii) to develop new indications for a Product with the same formulation and dosage
form and to develop additional support for the Product generally. 
 78 “Product Trademark(s)” means any
trademarks and trade names, whether or not registered, and any trademark applications, renewals, extensions or modifications thereto in the Territory together with all goodwill associated therewith, trade dress and packaging which are applied to or
used with Products, and any promotional materials relating thereto. 
 79 “Program Fee” has the meaning
set forth in Section 6.2 of this Agreement. 
 80 “Program Plans” means the Development Plans, the
Manufacturing/CMC Plans, and the Yearly Brand Plans. 
 81 “Proprietary Materials” means any tangible
chemical, biological or physical research materials. 
 82 “PTI” has the meaning set forth in the first
paragraph of this Agreement. 
 83 “PTI Background Technology” means any Technology that is useful in
the Field or that is actually used in the Development, manufacturing or Marketing of Products and that is Controlled by PTI on the Closing Date, expressly including all rights licensed to PTI pursuant to the DLA. 

84 “PTI Indemnitees” has the meaning set forth in Section 11.2 of this Agreement. 

85 “PTI Patent Rights” means all Patent Rights that are Controlled by PTI and that claim PTI Technology,
expressly including all rights licensed to PTI pursuant to the DLA, all as set forth on Schedule 85 hereto, which may be amended from time to time as necessary to accurately reflect the foregoing. 

86 “PTI Program Technology” means any Technology that is (a) Invented by employees of, or Consultants to,
PTI, alone or jointly with Third Parties (other than Consultants of King), in the conduct of the Development Program or (b) useful in the Field or that is actually used in the Development, manufacturing or Marketing of Products and that are
acquired by PTI after the Closing Date pursuant to a Third Party Agreement. 
 87 “PTI Technology”
means, collectively, PTI Background Technology and PTI Program Technology. 
 88 “Regulatory Approval”
means approval by the FDA or other Regulatory Authority to market a product in a regulatory jurisdiction. 

  
 - 8 -









 89 “Regulatory Authority” means the FDA, the Drug Enforcement
Administration, or any counterpart of such agencies outside the United States, or other national, supra-national, regional, state, or local regulatory agency, department, bureau, commission, council, or other governmental entity with authority over
the distribution, importation, exportation, manufacture, production, use, storage, transport, or clinical testing, pricing, or sale of a Product, including any device incorporating the Product. 

90 “Regulatory Filings” means, collectively, any and all INDs and drug master files, NDAs, applications for any
device incorporating the Product, applications for designation of a Product as an “Orphan Product(s)” under the Orphan Drug Act or any other similar filings (including any foreign equivalents and further including any related
correspondence and discussions), and all data contained therein, as may be required by or submitted to any Regulatory Authority for the Regulatory Approval. 
 91 “Remoxy” means a drug product in the Field that contains oxycodone as its opioid API and that is formulated using the SABER Technology. 

92 “ROW” means all countries and jurisdictions in the Territory, other than the U.S. Territory. 

93 “Saber Infringement” has the meaning set forth in Section 10.2(c) of this Agreement. 

94 “SABER Technology” means the pharmaceutical formulation technology and methods of use that are covered by the
rights granted to PTI pursuant to the DLA. 
 95 “Scientific Failure” has the meaning set forth in
Section 9.2.2(b) of this Agreement. 
 96 “Sublicensee” means any Third Party to which a Party or
both Parties grant a sublicense of some or all of the rights granted to such Party under this Agreement or the License Agreement, as permitted by this Agreement or the License Agreement. 

97 “Taxes” means, collectively, taxes, deductions, duties, levies, fees, or charges (including any interest or
penalties imposed thereon or related thereto. 
 98 “Technology” means and includes all inventions,
discoveries, improvements, trade secrets and proprietary methods and materials, including Proprietary Materials, whether or not patentable, relating to the Field, including (a) samples of, methods of production or use of, and structural and
functional information pertaining to, chemical compounds, proteins or other biological substances and (b) data, formulations, techniques and know-how (including any negative results). 

99 “Tech Transfer” means cooperation between the Parties in effecting an orderly transition of the matters in
question with respect to a Product, including transferring all information and files, and disclosing all necessary Technology, to the transferee. To the extent Applicable Law requires the transferee to control original documents, such original
documents will be provided to the transferee as part of the Tech Transfer. Unless otherwise provided, all costs associated with Tech Transfers will be deemed Collaboration Costs. 

100 “Term” means the term of this Agreement as set forth in Section 9.1 of this Agreement. 

101 “Termination Procedures” has the meaning set forth in Section 9.2.3 of this Agreement. 

102 “Territory” means worldwide, including the U.S. Territory, but excluding Australia and New Zealand.

 103 “Terminated Product” has the meaning set forth in Section 3.1.4 of this Agreement.

 104 “Third Party” means any person or entity other than King and PTI and their respective Affiliates.

 105 “Third Party Agreements” has the meaning set forth in Section 3.8 of this Agreement.


  
 - 9 -









 106 “U.S. Territory” means the United States, including Puerto Rico,
and any other U.S. protectorates, territories, and possessions. 
 107 “Valid Claim” means a claim of a
pending patent application or an issued unexpired patent which, in each case, shall not have been withdrawn, canceled or disclaimed, or held unpatentable, invalid or unenforceable by a court or other tribunal of competent jurisdiction in an
unappealed or unappealable decision. 
 108 “Yearly Brand Plans” means the written Marketing plans
(which shall include a detailed strategy and proposed timelines to be undertaken) describing the activities to be carried out by King during each applicable Calendar Year pursuant to this Agreement. Each Yearly Brand Plan will be set forth in a
written document prepared by King and reviewed by the JOC pursuant to Section 3.6 of this Agreement, and a separate Yearly Brand Plan will be generated and approved with respect to each Product. 

EXHIBIT A 
 LICENSE AGREEMENT 

  
 - 10 -









 Schedule 10.2(d) 
 (i) LIST OF PTI PUBLICATIONS 
 AAPM Poster – February 2005:
RemoxyTM, A Novel Drug Candidate Deters Oxycodone Abuse In Humans 
 World Pain Congress Poster – September 2004: Clinical
Pharmacokinetics of Oxycodone After Single and Multiple Doses of RemoxyTM, A Novel, Abuse-Resistant Long-Acting Oxycodone Formulation 

World Pain Congress Poster – September 2004: RemoxyTM, A Novel Drug Candidate, Deters Oxycodone Abuse In Humans 

Wall Street Journal Story – June 29, 2004: As Abuse of Painkillers Climbs, OxyContin Gets Reformulated, By David P. Hamilton To Thwart
Improper Use, Pain Therapeutics’ Version Can’t Be Dissolved, Crushed, By David P. Hamilton 
 Analyst Day Presentation in New
York – November 5, 2003: RemoxyTM: A New Drug Candidate 
 New York Times Story – November 5, 2003: Company
Said to Develop Substitute for Painkiller, By Andrew Pollack 
 Press Release – September 9,2005 

Pain Therapeutics Announces Positive Phase III Results 
 - RemoxyTM Meets Primary and Secondary Endpoints In Chronic Pain Study – 
 Press
Release – June 8, 2005 
 Pain Therapeutics Completes Patient Enrollment In A Phase III Study of RemoxyTM

 - Top-Line Results Expected In Third Quarter, Ahead of Schedule - 
 Press Release – December 23,2004 
 Pain Therapeutics Meets All
Milestones In 2004 
 – Pipeline Now Includes Three Novel Drug Candidates In Phase III – 

Press Release – December 6, 2004 
 Study Results Confirm RemoxyTM Is Significantly Less Abusable Than
OxyContin® 
 - Goal Is To Prevent Drug Abuse, Patient Misuse and Accidental Overdose - 
 Press Release
– September 2, 2004 
 Pain Therapeutics’ Remoxy Cleared For U.S. Clinical Trials 

Press Release – June 29, 2004 

Pain Therapeutics Demonstrates RemoxyTM Is Significantly Less Abusable Than OxyContin® 
 – Remoxy and OxyContin Are Expected to Provide Equal Pain Relief– 
 Press Release
– January 15, 2004 
 Pain Therapeutics’ New Drug Now In Clinical Testing 

- RemoxyTM Designed to Deter Oxycodone Abuse - 
 Press Release – November 5, 2003 
 Pain Therapeutics Announces
RemoxyTM A New Drug To Deter Oxycodone Abuse 

  

					
	(11091)	 		 	Schedule 10.2(d)
			
		 	- 11 -	 	









 (ii) LIST OF DURECT AUTHORS AND PUBLICATIONS 

(1) List of Durect Authors 
 J.W.
Gibson 
 F.W. Okumu 
 F. Theeuwes

 A.J. Tipton 
 S. Yum 

J. C. Middleton 
 (2) List of Durect
Publications 
 DUROS® Osmotic Pharmaceutical Systems for Parenteral & Site-Directed Therapy. J. Wright, S. Yum, RM. Johnson Drug Delivery Technology Magazine 2003
Vol 3 No 1: 64-73. 
 Pharmacokinetic Advantage of lntrapericardially Applied Substances in the Rat. J. Hermans, H. Van Essen, H.
Struijker-Boudier, R. Johnson, F. Theeuwes, J. Smits. The Journal of Pharmacology and Experimental Therapeutics. 2002; 301: 672-678. 

Applications of Continuous Site-Directed Drug Delivery. R. Johnson, A. Verity. Proceedings of the Western Pharmacology Society. 2002; 45:
219-222. 
 Evaluation of the SABERTM Delivery System for Sustained Release of Growth Hormone – Formulation
Design and In Vivo Assessment. F. Okumu, A. Daugherty, L. Dao, P. Felder, D. Brooks, S. Sane, S.A. Sullivan, A.J. Tipton, J. Cleland. Presented at the 28th International Symposium of The Controlled Release Society, 2001, June 23-27, San Diego, California.

 Gels. A.J. Tipton. Presented at the American Association of Pharmaceutical Scientists Workshop: Assuring Quality and Performance of
Sustained and Controlled Release Parenterals, 2001, April 19-20, Washington, D.C. 
 Drug Delivery from a Controlled Release
Aerosol: Effects of Formulation Variables. K.M. Carraway, S.K. Meador, S.A. Sullivan, J.W. Gibson, A.J. Tipton. Presented at the AAPS Annual Meeting and Exposition, 2000, October 29 - November 2, Indianapolis, Indiana. 

In Situ Gelling Systems to Deliver Peptides and Proteins. A.J. Tipton, Presented at the 5th
International Drug Delivery Technologies & Deal-Making Summit and Exposition, 2000, July 26-28, Princeton, New Jersey. 

Evaluation of SABERTM as a Local Delivery System for rh VEGF-Formulation Design and in vitro Assessment. F.W. Okumu, A.
Daugberty, S.A. Sullivan, A.J. Tipton, J.L. Cleland. Presented at the 27th International Meeting of The Controlled Release Society, 2000, July 7-13, Paris, France. 
 Incorporation of Polymer Microparticles into Sucrose Acetate Isobutyrate Reduces Burst and Extends Release. S.A. Sullivan, S.K. Meador, K.M. Carraway, A.J. Tipton, J. W. Gibson. Presented at the
27th International Meeting of The Controlled Release
Society, 2000, July 7-13, Paris, France. 
 Drug Release from a Novel Controlled Release Aerosol Based on Sucrose Acetate Isobutyrate.
K. Michelle Carraway, Stacey A. Sullivan, Stacey K. Meador, Julie C Williams, John W. Gibson, and Arthur J. Tipton. Presented at the AAPS Midwest Regional Meeting. 2000, May 22, Chicago, Illinois. 

  

					
	(11091)	 		 	Schedule 10.2(d)
			
		 	- 12 -	 	









 Local Delivery from a Novel Biodegradable In Situ Delivery System. Arthur J. Tipton, Stacey A.
Sullivan, K. Michelle Carraway, Dawn A. Smith, and John W. Gibson. Presented at the Sixth World Biomaterials Congress, 2000, May 15-20, Kamuela, Hawaii. 
 SABERTM Provides Burst Free Release of Growth Hormone from PLGA Microspheres. F.W. Okumu, S. Darling, L.N. Dao, P. J. Fielder, S.A. Sullivan, A.J. Tipton, and J.L. Cleland. Presented at the
Millennial World Congress of Pharmaceutical Sciences, 2000, April 16-20, San Francisco, California. 
 Extended Release of Human
Growth Hormone Suspended in SABERTM Formulation Design and In Vitro Assessment. S. Darling, F.W. Okumu, S.A. Sullivan, A.J. Tipton, and J.L. Cleland. Presented at the Millennial World Congress of Pharmaceutical Sciences,
2000, April 16-20, San Francisco, California. 
 Depot Delivery of Proteins in the New Millennium: From Microspheres to injectable
Gels. Jeffrey L, Cleland, OluFumni L. Johnson, Susan Darling, Arthur J. Tipton, Gaylen M. Zentner, Stacey Sullivan, John Gibson, and Franklin W. Okumu. Presented at the 6th European Symposium on Controlled Drug Delivery,
2000, April 12, Noordwijk Aan Zee, The Netherlands. 
 In Situ Gelling Formulations. Arthur J. Tipton and Richard L. Dunn. In:
Sustained Release Injectable Products, edited by Judy Senior and Michael Radomsky, Interpharm Press, Inc., Buffalo Grove, Illinois, 2000. 
 Peptide Delivery from an In Situ Gelling System Based on Sucrose Acetate Isobutyrate. A. J. Tipton. Invited lecture at the AAPS Annual Meeting and Exposition, 1999, November 14-18, New
Orleans, Louisiana. 
 Sustained Release of Lysozyme from the SABER Delivery System. S.A. Sullivan, S.K. Meador, K.M. Carraway, J.C.
Williams, J.W. Gibson, and A.J. Tipton. Presented at the AAPS Annual Meeting and Exposition, 1999, November 14-18, New Orleans, Louisiana. 
 Oral Controlled Release of Antiretrovirals using the SABER Delivery System Incorporated into Soft Gelatin Capsules. K.M. Carraway, S.A. Sullivan, J.W. Gibson, and A.J. Tipton. Presented at the AAPS
Annual Meeting and Exposition, 1999, November 14-18, New Orleans, Louisiana. 
 Effects of Formulation Variables on Controlled
Release of Paclitaxel and other Chemotherapeutic Agents from a Novel Delivery System. J.W. Gibson, S.A. Sullivan, K.M. Carraway, and A.J. Tipton. Presented at the AAPS Annual Meeting and Exposition, 1999, November 14-18, New Orleans,
Louisiana. 
 Biodegradable Delivery Systems for Estradiol: Comparison Between Poly(DL-lactide) Microspheres and the
SABER Delivery System. C.A. Johnson, D.L. Thompson, Jr., S.A. Sullivan, J.W. Gibson, A.J. Tipton, B.W. Simon, and P.J. Burns. Presented at the 26th International Meeting of The Controlled Release Society, 1999, June 20-25, Boston, Massachusetts.

 Evaluation of the SABER Delivery System for the Controlled Release of Deslorelin; Effect of Dose in Estrogen Primed
Ovarectomized Gilts. R. Barb, R. Kreaeling, G. Rampacek, D. Thompson, Jr., J. Gibson, S. Sullivan, B. Simon, and P.J. Burns. Presented at the 26th International lnternational Meeting of The Controlled Release Society, 1999, June 20-25, Boston,
Massachusetts. 
 Induction of Mucosal IgA Specific for SeMF3 of Streptococcus equi with Intranasal Vaccination Using a
Sucrose Acetate Isobutyrate Based Delivery System. J. Nally, S. Artiushin, A. Sheoran, J. Timoney, J. Gibson, S. Sullivan, R. Gilley, B. Simon, and P.J. Burns. Presented at the 26th International Meeting of The Controlled Release Society,
1999, June 20-25, Boston, Massachusetts. 

  

					
	(11091)	 		 	Schedule 10.2(d)
			
		 	- 13 -	 	









 New Delivery – Extension of Existing Products. A.J. Tipton. Invited Lecture at the AAPS
Eastern Regional Meeting, 1999, June 10-11, Paisippany, New Jersey. 
 Long-term Stability of Biodegradable
Polymers. C.T. Williams, C.S. Martin, P.P. Kines, R.P. Swaim, D.R. Whitfield, and J.Y.Williams. Presented at the
18th Annual Southern Biomedical Engineering Conference,
1999, May 21-23, Clemson University, South Carolina. 
 In Vitro and In Vivo Evaluation of a Novel In Situ-Forming Parenteral
Delivery System. J.W. Gibson, S.A. Sullivan, P.J. Burns, and A.J. Tipton. Poster presented at the meeting of Recent Advances in Drug Delivery Systems, 1999, February 22-25, Salt Lake City, Utah. 

Sustained Release of Bupivacaine from the SABER Delivery System. S.A. Sullivan, J. W. Gibson, and A.J. Tipton. Presented at the AAPS Annual
Meeting and Exposition, 1998, November 15-19, San Francisco, California. 
 Sustained Release of Orally
Administered Active Using SABERTM Delivery System Incorporated into Soft Gelatin Capsules. S.A. Sullivan, J.C. Yarbrough, R.W. Fengl, A.J. Tipton, and J.W. Gibson. Presented at the 25th International Meeting of The Controlled Release Society, 1998, June 21-26, Las Vegas, Nevada. 

Pharmacodynamic Evaluation of Biodegradable Estradiol-17b Microspheres and Prostaglandin F2a for the control of Estrus and
Ovulation in Gilts, R. Cushman, J.H. Britt, P. Davis, U. Boonyaprakob, V. Hedgpeth, J, Gibson, B. Hudson, and P.J. Burns. Presented at the 25th International Meeting of The Controlled Release Society, 1998, June 21-26, Las Vegas, Nevada. 

Sustained Release of Progesterone and Estradiol From the SABER TM Delivery System: In Vitro and In Vivo Release Rates.
S.A. Sullivan, J.W. Gibson, P.J. Burns, L. Franz, E.L. Squires, D.L. Thompson, and A.J. Tipton. Presented at the
25th International Meeting of The Controlled Release
Society, 1998, June 21-26, Las Vegas, Nevada. 
 Evaluation of the SABERTM Delivery System for the
Controlled Release of the GnRH Analog Deslorelin for Advancing Ovulation in Mares: Effect of Gamma Radiation. R. Betschart, J. Fleury, E.L. Squires, T. Nett, J. Gibson, S. Sullivan, A. Tipton, and P.J. Burns. Presented at the 25th International Meeting of The Controlled Release Society,
1998, June 21-26, Las Vegas, Nevada. 
 Evaluation of the SABERTM Delivery System for the Controlled
Release of Deslorelin for Advancing Ovulation in the Mare: Effects of Formulation & Dose. J. Fleury,. E.L. Squires, R. Betschart, J. Gibson, S. Sullivan, A. Tipton, and P.J. Burns. Presented at the 25th International Meeting of The Controlled Release Society,
1998, June 21-26, Las Vegas, Nevada. 
 Synthetic Biodegradable Polymers as Medical Devices. John C. Middleton and Arthur J.
Tipton. Medical Plastics and Biomaterials, 1998, March/April, 31-38. To view this paper, please click here. 

Long-Term Stability of Biodegradable Polymers. C.T. Williams, J.C. Middleton, K.R. Sims, R.P. Swaim, D.R. Whitfield, and J.C.
Yarbrough. Presented at the 17th Southern Biomedical
Engineering Conference, 1998, February 6-8, San Antonio, Texas. 
 Drug Delivery from In Situ Formed Depot
Systems. A.J. Tipton, Invited Lecture at the 33rd
Annual AAPS Pharmaceutical Technologies Section Arden House Conference, 1998, January 18-23, Harriman, New York. 

  

					
	(11091)	 		 	Schedule 10.2(d)
			
		 	- 14 -	 	









 Delivery of Taxolâ and Other Antineoplastic Agents from a Novel System Based on Sucrose Acetate
Isobutyrate. S.A. Sullivan, R.M. Gilley, J.W. Gibson and A.J. Tipton. Pharm. Res., 1997, 14 (11), 291. 

Pharmacodynamic Evaluation of the SABERTM Delivery System for the Controlled Release of the GnRH Analogue Deslorelin Acetate
for Advancing Ovulation in Cyclic Mares. P.Burns, D. Thompson, F. Donadue, L. Kincald, B. Leise, J. Gibson, R. Swaim, and A. Tipton. Presented at the 24th International Meeting of The Controlled Release Society, 1997, June 16-19, Stockholm. 

Evaluation of the Saber Delivery System for the Release of GnRH Analog Deslorelin Acetate for Advancing Ovulation in the Mare.
F.J. Donadue, D.L. Thompson, P.J. Burns, A.J. Tipton, J.W. Gibson, R.P. Swaim, L.A. Kincald, and B.S. Leise. Presented at the 15th Annual Meeting of The Equine Nutrition and Physiology Society Meeting, 1997, May 29-31, Fort Worth, Texas.

 A Novel Parenteral Delivery System. Dawn Alison Smith and Arthur J. Tipton. Pharm. Res. 1996, 13(9), 300. 

Evaluation of a New Continuous Process for Preparation of Progesterone and Estradiol Microspheres: An In Vivo Pharmacokinetics Study. P.J. Burns,
T.R. Tice, D. Mason, D. Love, T. Ferrell, J. Gibson, K. Dippert, and E. Squires. The Controlled Release Society, Advances in Controlled Delivery, 1996, August 21-22, Baltimore, Maryland. 

Controlled Release of Diclofenac-Na from Cellulose Ester Microspheres. J. A. Nabors. W.K. Hopkins, M.E. Hudson, J. Gibson, D.M. Wyatt, and
A.J. Tipton. Pharm. Res. 1994, 11(10). 295 

  

					
	(11091)	 		 	Schedule 10.2(d)
			
		 	- 15 -	 	









 Schedule 22 

Crain Shen Existing Patents 
  

	1.	Method of Simultaneously Enhancing Analgesic Potency and Attenuating Dependence Liability Caused by Morphine and Other Opioid Agonists 


United States – Patent No. 5,472,943 
 Australia – Patent No. 691515 
 Canada – Application
No. 2,168,262 
 Europe – Application No. 04017033.4 

Japan – Application No. 505899 
  

	2.	Method of Simultaneously Enhancing Analgesic Potency and Attenuating Dependence Liability Caused by Exogenous and Endogenous Opioid Agonists


 United States – Patent No. RE 36,547 

[Reexamination Certificate No. RE 36,547 Fl] 
 Australia – Patent Acceptance No. 782475 
 Australia – Patent
Acceptance No. 782665 
 Canada – Application No. 2,195,122 

Europe – Application No. 05008904.4 
 Japan – Application No. 08-505298 
  

	3.	Method of Simultaneously Enhancing Analgesic Potency and Attenuating Dependence Liability Caused by Morphine and Other Bimodally-Acting Opioid Agonists


 United States – Patent No. 5,580,876 

[Reexamination Certificate No. 5,580,876 Cl] 
 United States – Patent No. 5,767,125 
 [Reexamination Certificate
No. 5,767,125 Cl] 
 United States – Patent No. 6,096,756 

[Reexamination Certificate No. 6,096,756 Cl] 
 United States – Patent No. 6,362,194 
 [Reexamination
No. 90/006,475 (Certificate to be issued)] 
 United States – Application No. 10/319,789 

United States – Application No. 10/925,368 
  

	4.	Method and Composition for Treating Irritable Bowel Syndrome Using Low Doses of Opioid Receptor Antagonists 


United States – Patent No. 6,194,382 
 United States – Patent No. 6,395,705 
 United States – Patent
No. 6,737,400 
 United States – Application No. 10/807,508 

Australia – Patent No. 780013 
 Australia – Application No. 2005202245 
 Canada – Application
No. 2,365,391 
 Europe – Application No. 00915994.8 

Japan – Application No. 2000-602060 
 Schedule 22 

  

					
		 	- 16 -	 	









 New Zealand – Patent No. 514446 

 

	5.	Methods for Increasing Analgesic Potency and Attenuating Adverse Excitatory Effects of Bimodally-Acting Opioid Agonists by Inhibiting GMl-Ganglioside


 United States – Application No. 10/459,418 

Australia – Application No. 2002305066 
 Canada – Application No. 2,441,889 
 Europe – Application
No. 02733865.6 
 Japan – Application No. 2002-574904 

 

	6.	Use of Excitatory Opioid Receptor Antagonists to Prevent Growth Factor-Induced Hyperalgesia 


United States – Patent No. 5,585,348 
  

	7.	Compositions and Methods for Enhancing Analgesic Potency of Tramadol and Attenuating its Adverse Side Effects 


United States – Patent No. 6,765,010 
 United States – Application No. 10/894,349 
 Australia – Patent
Acceptance No. 782533 
 Canada – Application No. 2,373,348 

Europe – Application No. 00932162.1 
 Japan – Application No. 2000-616766 
  

	8.	Novel Composition and Methods for Enhancing Potency or Reducing Adverse Side Effects of Opioid Agonists 


United States – Application No. 10/228,835 
 Australia – Application No. 2001259560 
 Canada – Application
No. 2,408,098 
 Europe – Application No. 01933110.7 

Japan – Application No. 2001-581804 
  

	9.	Opioid Antagonist Compositions and Dosage Forms 

 United States – Application No. 10,119,615 
 Australia – Application
No. 2001259458 
 Canada – Application No. 2,408,106 

Europe – Application No. 01932983.8 
 Japan – Application No. 2001-581910 
  

	10.	Inhibitors of ABC Drug Transporters at the Blood-Brain Barrier 

 United States – Application No. 10/000,113 
 Australia – Application
No. 2002239427 
 Canada – Application No. 2,427,330 

Europe – Application No. 01987187.0 
 Japan – Application No. 2002-544063 
 Schedule 22 

  

					
		 	- 17 -	 	










	11.	Inhibitors of ABC Drug Transporters in Cancer Cells 

 United States – Application No. 10/159,012 
  

	12.	Inhibitors of ABC Drug Transporters in Microbial Cells 

 United States – Application No. 10/000,107 
 United States –
Application No. 10/159,212 
  

	13.	Oral Dosage Forms with Therapeutically Active Agents in Controlled Release Cores And Immediate Release Gelatin Capsule Coats 


United States – Patent Application No. 10/742,672 
 Australia – Application No. 2003301121 
 Canada – Application
No. 2,510,465 
 Europe – Application No. 03813786.5 

 

	14.	Methods and Materials for the Treatment of Pain Comprising Opioid Antagonists 


United States – Application No. 10/825,257 
 Australia 
 Canada 

Europe 
  

	15.	Methods and Materials Useful for the Treatment of Arthritic Conditions, Inflammation Associated with a Chronic Condition or Chronic Pain


 United States – Application No. 10/966,703 

PCT – Application No. PCT/US2004/34184 
  

	16.	Methods and Materials for the Treatment of Pain Comprising Opioid Antagonists 


United States – Application No, 11/089,283 
 PCT – Application No. PCT/US2005/10043 
 Schedule 22 

  

					
		 	- 18 -	 	









 Schedule 53 

Joint Patent Rights 

None 
 Schedule 53


  

					
		 	- 19 -	 	









 Schedule 58 

King Patent Rights 

None 
 Schedule 58


  

					
		 	- 20 -	 	









 Schedule 85 

PTI Patent Rights 
  

	1.	High Viscosity Liquid Controlled Delivery System 

 United States – Patent No. 5,747,058 
 Australia – Patent
No. 698281 
 Brazil – Application No. PI9609033-2 

Canada – Patent No. 2,222,567 
 China – Application No. 96195895.2 
 Hong Kong – Application
No. 99100601.3 
 Europe – Patent No. 1006935 

Europe – Application No. 05075143.7 (Divisional of EP 1006935) 

Japan – Application No. 09-502181 
 Mexico – Application No. 979606 
 New Zealand – Patent No. 311405

 New Zealand – Application No. 536473 (Divisional of NZ 311405) 

 

	2.	High Viscosity Liquid Controlled Delivery System as a Device 

 United States – Patent No. 5,968,542 
 Australia – Application
No. 94750/98 
 Brazil – Application No. PI9812313-0 

Canada – Application No. 2,303,442 
 China – Application No. 98810977.8 
 Europe – Application
No. 98948113.0 
 Japan – Application No. 2000-511528 

Mexico – Application No. 002545 
 New Zealand – Patent No. 503366 
  

	3.	High Viscosity Liquid Controlled Delivery System and Medical or Surgical Device 


United States – Patent No. 6,413,536 
 United States – Application No. 09/699,002 (Divisional of US 6,413,536) 

Australia – Application No. 73319/00 
 Canada – Application No. 2,382,540 
 Europe – Application
No. 9613858.9 (to be granted as EP 1212092) 
 Japan – Application No. 2001-520145 

 

	4.	High Viscosity Liquid Controlled Delivery System and Medical or Surgical Device 


United States – Application No. 10/316,441 (Continuation-in-part of 09/699,002) 

Schedule 85 

  

					
		 	- 21 -	 	










	5.	Oral Drug Delivery System 


United States – Application No. 60/433,116 
 United States – Application No. 60/517,464 
 United States –
Application No. 10/737,144 
 Canada – Application No. 2,507,522 

China 
 Europe
– Application No. 03799943.0 
 India 
 Israel 
 Japan – Application No. 2005-508335 

Schedule 85 

  

					
		 	- 22 -